Endo Tomoyuki
| Hokkaido University Hospital Infection Control Center | Professor |
Last Updated :2026/01/07
■Researcher basic information
Researchmap personal page
J-Global ID
Educational Organization
- Master's degree program, Graduate School of Medicine
- Doctoral (PhD) degree program, Graduate School of Medicine
■Research activity information
Papers
- FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
Toshihiro Matsukawa, Masahiro Onozawa, Takeshi Kondo, Minoru Kanaya, Daisuke Hidaka, Shuichi Ota, Akio Mori, Akio Shigematsu, Takuto Miyagishima, Yasutaka Kakinoki, Junichi Hashiguchi, Satoshi Yamamoto, Masayo Yamamoto, Kentaro Wakasa, Mutsumi Takahata, Toshimichi Ishihara, Yoshihito Haseyama, Akihito Fujimi, Tetsuya Igarashi, Takehiro Sarashina, Satoshi Iyama, Ryoji Kobayashi, Hajime Sakai, Katsuya Fujimoto, Junki Inamura, Yuji Kanisawa, Shinsuke Hirabayashi, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima
Annals of hematology, 103, 12, 5333, 5340, Dec. 2024, [International Magazine]
English, Scientific journal, Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting. We retrospectively analyzed 139 patients with FLT3-ITD-positive AML between 2012 and 2021. The median age was 63 years. In the propensity score-matched cohort, FLT3 inhibitors improved overall survival (OS) compared with patients treated without FLT3 inhibitors (3-year OS: 33.7% vs. 25.8%, p = 0.021). Patients who underwent HCT had superior outcomes to those without HCT (3-year OS: 45.3% vs. 2.2%, p < 0.0001). The combination of FLT3 inhibitors and HCT resulted in the highest OS and relapse-free survival (RFS) rates (3-year OS: 62.4%; 3-year RFS: 44.4%). Disease status before transplantation did not predict the prognosis, but use of FLT3 inhibitors increased survival in patients without complete remission before HCT. These results demonstrate the clinical impact of FLT3 inhibitors on survival outcomes in patients with FLT3-ITD-positive AML, particularly when combined with HCT. FLT3 inhibitors can improve the prognosis of AML with FLT3 mutations, especially in patients who undergo HCT. - HIV感染合併血友病患者の運動機能評価およびリハビリテーションの有用性
遠藤 知之, 渡部 恵子, 原田 裕子, 由利 真, 千田 尊子, 後藤 秀樹, 松川 敏大, 荒 隆英, 長谷川 祐太, 宮島 徹, 長井 惇, 森木 朝子, 藤谷 順子, 豊嶋 崇徳
日本エイズ学会誌, 26, 4, 380, 380, (一社)日本エイズ学会, Nov. 2024
Japanese - AIDS患者の髄液病原体網羅的解析を目的としたマルチプレックスPCRの有用性についての検討
松川 敏大, 遠藤 知之, 森木 朝子, 長井 惇, 宮島 徹, 長谷川 祐太, 荒 隆英, 後藤 秀樹, 豊嶋 崇徳
日本エイズ学会誌, 26, 4, 457, 457, (一社)日本エイズ学会, Nov. 2024
Japanese - ART療法が奏効した難治性サイトメガロウイルス腸炎の1例
長谷川 祐太, 遠藤 知之, 宮島 徹, 長井 惇, 森木 朝子, 松川 敏大, 荒 隆英, 後藤 秀樹, 豊嶋 崇徳
日本エイズ学会誌, 26, 4, 459, 459, (一社)日本エイズ学会, Nov. 2024
Japanese - 北海道ブロック「HIV/AIDS出張研修」 12年間の実践報告
渡部 恵子, センテノ田村 恵子, 遠藤 知之, 武内 阿味, 熊谷 泰恵, 石田 陽子, 尾谷 ゆか, 山口 みなみ, 北村 末季, 松川 敏大, 長谷川 祐太, 後藤 秀樹, 豊嶋 崇徳, 三宅 亜矢
日本エイズ学会誌, 26, 4, 514, 514, (一社)日本エイズ学会, Nov. 2024
Japanese - 簡易懸濁法でドラビリンとドルテグラビルを投与後に血漿中薬物濃度を測定した一例
田澤 佑基, 松川 敏大, 新井 崇之, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 26, 4, 402, 402, (一社)日本エイズ学会, Nov. 2024
Japanese - 持続性注射薬カボテグラビル+リルピビリン(CAB+RPV)使用患者の臨床的特徴
新井 崇之, 田澤 佑基, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 26, 4, 417, 417, (一社)日本エイズ学会, Nov. 2024
Japanese - Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.
Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takanori Teshima, Yibin Yang, Masao Nakagawa
Leukemia, 21 Oct. 2024, [International Magazine]
English, Scientific journal - HLA半合致移植を施行したShwachman-Diamond症候群(SDS)を背景とした急性骨髄性白血病
塚本 しほり, 中川 雅夫, 小野澤 真弘, 南谷 泰仁, 小島 圭祐, 原田 知弥, 荒 隆英, 松川 敏大, 白鳥 聡一, 遠藤 知之, 豊嶋 崇徳
臨床血液, 65, 10, 1329, 1329, (一社)日本血液学会-東京事務局, Oct. 2024
Japanese - FLT3阻害薬は投与時期に関わらずFLT3変異AMLの予後を延長する
松川 敏大, 近藤 健, 日高 大輔, 太田 秀一, 金谷 穣, 盛 暁生, 重松 明男, 宮城島 拓人, 柿木 康孝, 橋口 淳一, 山本 聡, 山本 昌代, 若狭 健太郎, 高畑 むつみ, 石原 敏道, 長谷山 美仁, 藤見 章仁, 五十嵐 哲祥, 更科 岳大, 井山 諭, 小林 良二, 酒井 基, 藤本 勝也, 稲村 純季, 蟹澤 祐司, 平林 真介, 小野澤 真弘, 遠藤 知之, 豊嶋 崇徳
日本血液学会学術集会, 86回, O1, 5, (一社)日本血液学会, Oct. 2024
English - HIV陽性者における性感染症の実態
松川 敏大, 遠藤 知之, 長井 惇, 宮島 徹, 須藤 啓斗, 長谷川 祐太, 荒 隆英, 後藤 秀樹, 豊嶋 崇徳
日本エイズ学会誌, 26, 3, 132, 138, (一社)日本エイズ学会, Aug. 2024
Japanese - Dolutegravir/lamivudineへの薬剤変更における薬剤師介入の効果
田澤 佑基, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 26, 2, 77, 84, (一社)日本エイズ学会, May 2024
Japanese - Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
Masahiro Chiba, Joji Shimono, Keito Suto, Takashi Ishio, Tomoyuki Endo, Hideki Goto, Hiroo Hasegawa, Michiyuki Maeda, Takanori Teshima, Yibin Yang, Masao Nakagawa
Blood, 24 Dec. 2023, [International Magazine]
English, Scientific journal, Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis and limited treatment options. Programmed cell death ligand 1(PD-L1) is recognized to be involved in the pathobiology of ATLL. However, what molecules control PD-L1 expression and whether genetic or pharmacological intervention might modify PD-L1 expression in ATLL cells is still unknown. In order to comprehend the regulatory mechanisms of PD-L1 expression in ATLL cells, we performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening in this work. In ATLL cells, we discovered that the neddylation-associated genes NEDD8, NAE1, UBA3, and CUL3 negatively regulated PD-L1 expression while STAT3 positively did so in ATLL cells. We verified, in line with the genetic results, that treatment with the JAK1/2 inhibitor ruxolitinib or the neddylation pathway inhibitor pevonedistat resulted in a decrease in PD-L1 expression in ATLL cells or an increase in it. It is significant that these results held true regardless of whether ATLL cells had the PD-L1 3' structural variant, a known genetic anomaly that promotes PD-L1 overexpression in certain primary ATLL patients. Pevonedistat alone showed cytotoxicity for ATLL cells, but compared to each single modality, pevonedistat improved the cytotoxic effects of the anti-PD-L1 monoclonal antibody Avelumab and chimeric antigen receptor T-cells targeting PD-L1 in vitro. As a result, our work provided insight into a portion of the complex regulatory mechanisms governing PD-L1 expression in ATLL cells and demonstrated the in vitro preliminary preclinical efficacy of PD-L1-directed immunotherapies by using pevonedistat to upregulate PD-L1 in ATLL cells. - Efficacy and Safety of Single-dose Pegfilgrastim for CD34+ Cell Mobilization in Healthy Volunteers: A Phase 2 Study.
Hideki Goto, Junichi Sugita, Yuta Hasegawa, Koji Hayasaka, Kana Sunagoya, Rie Hatase, Mutsumi Nishida, Yuki Ichihashi, Mitsuhiko Odera, Hajime Senjo, Shota Yokoyama, Takahide Ara, Souichi Shiratori, Tomoyuki Endo, Masayuki Hino, Yoshinobu Maeda, Masashi Sawa, Norihiro Sato, Takanori Teshima
Transplantation, 28 Nov. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: Pegfilgrastim, a long-acting form of granulocyte-colony stimulating factor, with a convenient single-injection dosage, is being investigated for peripheral blood stem cell (PBSC) mobilization in healthy volunteers. However, data on the adequate dose of pegfilgrastim for PBSC mobilization are limited. This phase 2, single-arm study evaluated the efficacy and safety of pegfilgrastim for PBSC mobilization in healthy volunteers. METHODS: The study comprised 2 phases: pilot (steps 1-3, dose escalation, a single subcutaneous dose of 3.6, 7.2, and 10.8 mg pegfilgrastim, respectively) and evaluation (step 4, efficacy and safety assessments). The primary endpoint was the proportion of subjects who achieved mobilization of ≥20 × 106/L cluster of differentiation 34 positive (CD34+) cells. RESULTS: Thirty-five subjects (6 each in steps 1 and 2 and 23 in step 4) were included. In the pilot phase, step 3 with a 10.8 mg dose was not conducted due to favorable outcomes in step 2 (desired CD34+ cell count), at 7.2 mg pegfilgrastim, which was identified as the optimal dose for the evaluation phase. In the evaluation phase, successful CD34+ mobilization was achieved in all 23 subjects. The mean peripheral blood CD34+ cells count peaked on day 5. Back pain, thrombocytopenia, transient elevations of alkaline phosphatase, and lactate dehydrogenase were the most common adverse events. All adverse events were mild, and none led to study discontinuation. CONCLUSIONS: A single-dose pegfilgrastim successfully mobilized an optimal number of CD34+ cells and was well tolerated. Pegfilgrastim could be an alternative option for PBSC mobilization in healthy volunteers. The trial was registered at www.clinicaltrials.gov (NCT03993639). - 2022年度HIV-1薬剤耐性検査外部精度評価の報告
吉田 繁, 松田 昌和, 今橋 真弓, 岡田 清美, 齊藤 浩一, 林田 庸総, 佐藤 かおり, 藤澤 真一, 遠藤 知之, 西澤 雅子, 椎野 禎一郎, 潟永 博之, 豊嶋 崇徳, 杉浦 亙, 吉村 和久, 菊地 正
日本エイズ学会誌, 25, 4, 443, 443, (一社)日本エイズ学会, Nov. 2023
Japanese - HIV陽性者における性感染症の実態
松川 敏大, 遠藤 知之, 長井 惇, 宮島 徹, 須藤 啓斗, 長谷川 祐太, 荒 隆英, 後藤 秀樹, 豊嶋 崇徳
日本エイズ学会誌, 25, 4, 441, 441, (一社)日本エイズ学会, Nov. 2023
Japanese - 2剤療法施行中のHIV陽性者におけるBlipおよびTND(Target Not Detected)維持率の検討
遠藤 知之, 後藤 秀樹, 松川 敏大, 荒 隆英, 長谷川 祐太, 須藤 啓斗, 宮島 徹, 長井 惇, 豊嶋 崇徳
日本エイズ学会誌, 25, 4, 498, 498, (一社)日本エイズ学会, Nov. 2023
Japanese - 食道胃接合部癌術後に食道狭窄を繰り返す症例に対して持効性注射薬カボテグラビル+リルピビリン(CAB+RPV)を導入した一例
田澤 佑基, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 25, 4, 483, 483, (一社)日本エイズ学会, Nov. 2023
Japanese - Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study
Shunsuke Uno, Hiroyuki Gatanaga, Tsunefusa Hayashida, Mayumi Imahashi, Rumi Minami, Michiko Koga, Sei Samukawa, Dai Watanabe, Teruhisa Fujii, Masao Tateyama, Hideta Nakamura, Shuzo Matsushita, Yusuke Yoshino, Tomoyuki Endo, Masahide Horiba, Toshibumi Taniguchi, Hiroshi Moro, Hidetoshi Igari, Shigeru Yoshida, Takanori Teshima, Hideaki Nakajima, Masako Nishizawa, Yoshiyuki Yokomaku, Yasumasa Iwatani, Atsuko Hachiya, Shingo Kato, Naoki Hasegawa, Kazuhisa Yoshimura, Wataru Sugiura, Tadashi Kikuchi
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 19 Oct. 2023, [Peer-reviewed]
Scientific journal, Abstract
Background
Integrase strand transfer inhibitors (INSTIs) are recommended as first-line ART for people living with HIV (PLWH) in most guidelines. The INSTI-resistance-associated mutation E157Q, a highly prevalent (2%–5%) polymorphism of the HIV-1 (human immunodeficiency virus type 1) integrase gene, has limited data on optimal first-line ART regimens. We assessed the virological outcomes of various first-line ART regimens in PLWH with E157Q in real-world settings.
Methods
A multicentre retrospective observational study was conducted on PLWH who underwent integrase genotypic drug-resistance testing before ART initiation between 2008 and 2019 and were found to have E157Q. Viral suppression (<50 copies/mL) rate at 24 and 48 weeks, time to viral suppression and time to viral rebound (≥100 copies/mL) were compared among the first-line ART regimens.
Results
E157Q was detected in 167 (4.1%) of 4043 ART-naïve PLWH. Among them, 144 had available clinical data after ART initiation with a median follow-up of 1888 days. Forty-five started protease inhibitors + 2 NRTIs (PI group), 33 started first-generation INSTI (raltegravir or elvitegravir/cobicistat) + 2 NRTIs (INSTI-1 group), 58 started once-daily second-generation INSTI (dolutegravir or bictegravir) + 2 NRTIs (INSTI-2 group) and eight started other regimens. In the multivariate analysis, the INSTI-2 group showed similar or favourable outcomes compared with the PI group for viral suppression rates, time to viral suppression and time to viral rebound. Two cases in the INSTI-1 group experienced virological failure.
Conclusions
The general guideline recommendation of second-generation INSTI-based first-line ART for most PLWH is also applicable to PLWH harbouring E157Q. - Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
Preeti Prerna M Vaswani, Masahiro Onozawa, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Toshihiro Matsukawa, Atsushi Yasumoto, Souichi Shiratori, Hideki Goto, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima
Bone marrow transplantation, 05 Sep. 2023, [International Magazine]
English - Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
Hiroyuki Kimura, Masahiro Onozawa, Shota Yoshida, Naoki Miyashita, Shota Yokoyama, Toshihiro Matsukawa, Shinsuke Hirabayashi, Hideki Goto, Tomoyuki Endo, Satoshi Oguri, Shinichi Fujisawa, Akio Mori, Takeshi Kondo, Daisuke Hidaka, Kohei Okada, Shuichi Ota, Yasutaka Kakinoki, Yutaka Tsutsumi, Satoshi Yamamoto, Takuto Miyagishima, Junichi Hashiguchi, Takahiro Nagashima, Makoto Ibata, Kentaro Wakasa, Yoshihito Haseyama, Katsuya Fujimoto, Toshimichi Ishihara, Hajime Sakai, Takanori Teshima
Annals of hematology, 19 Aug. 2023, [International Magazine]
English, Scientific journal, IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each deletion has not been fully elucidated. We retrospectively analyzed 117 patients with adult B-ALL including 60 patients with BCR::ABL1-positive B-ALL and 57 patients with BCR::ABL1-negative B-ALL by the fluorescence in situ hybridization (FISH) method for IKZF1 deletion and multiplex PCR for the 4 most common IKZF1 deletions (∆4-7, ∆2-7, ∆2-8, and ∆4-8). Samples, in which IKZF1 deletion was detected by FISH but a specific type of deletion was not identified by the PCR, were categorized as "other." Patients were classified into a DN group that had at least 1 allele of ∆4-7 (n = 23), LOF and other group (n = 40), and wildtype group (n = 54). DN type IKZF1 deletions were found in 33.3% of BCR::ABL1-positive cases and 5.2% of BCR::ABL1-negative cases. LOF and other type IKZF1 deletions were found in 43.4% of BCR::ABL1-positive cases and 24.6% of BCR::ABL1-negative cases. Patients with the DN group showed significantly higher overall survival (OS) than that of the LOF and other and WT groups (P = 0.011). Multivariate analysis including age, WBC counts, complex karyotype, and DN type IKZF1 deletion showed that the DN type of IKZF1 deletion (HR = 0.22, P = 0.013) had a positive impact and age ≥ 65 (HR = 1.92, P = 0.029) had a negative impact on OS. The prognostic impact of IKZF1 deletion depends on the type of deletion and DN type of IKZF1 deletion showed better prognosis in adult B-ALL patients.Clinical trial registration This study was part of a prospective observational study (Hokkaido Leukemia Net, UMIN000048611). It was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Hokkaido University Hospital (#015-0344). - Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
Hajime Senjo, Shinpei Harada, Shimpei I Kubota, Yuki Tanaka, Takahiro Tateno, Zixuan Zhang, Satomi Okada, Xuanzhong Chen, Ryo Kikuchi, Naoki Miyashita, Masahiro Onozawa, Hideki Goto, Tomoyuki Endo, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Yoshinori Hasegawa, Masaaki Murakami, Takanori Teshima, Daigo Hashimoto
Blood, 22 May 2023, [International Magazine]
English, Scientific journal, Calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal-Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory-Tex), expressing both inhibitory receptors and effector molecules, into terminal-Tex, and inhibited tolerance induction. Adoptive transfer of transitory-Tex, but not terminal-Tex, into secondary recipients developed chronic GVHD. Transitory-Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory-Tex, not terminal-Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse. - ドルテグラビル/アバカビル/ラミブジン(DTG/ABC/3TC)からDTG/3TCへの薬剤変更における薬剤師介入効果の検証
田澤 佑基, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 24, 4, 383, 383, (一社)日本エイズ学会, Nov. 2022
Japanese - ドルテグラビル/アバカビル/ラミブジン(DTG/ABC/3TC)からDTG/3TCへの薬剤変更における薬剤師介入効果の検証
田澤 佑基, 遠藤 知之, 武隈 洋, 菅原 満
日本エイズ学会誌, 24, 4, 383, 383, (一社)日本エイズ学会, Nov. 2022
Japanese - 大腿骨人工骨頭インプラント周囲に発症したALK陰性未分化大細胞型リンパ腫の1例
森 祐斗, 荒 隆英, 中川 雅夫, 吉田 匠汰, 斎藤 祐美花, 横山 翔大, 松川 敏大, 白鳥 聡一, 遠藤 知之, 豊嶋 崇徳
臨床血液, 63, 11, 1592, 1593, (一社)日本血液学会-東京事務局, Nov. 2022
Japanese - Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
Takahide Ara, Tomoyuki Endo, Hideki Goto, Kohei Kasahara, Yuta Hasegawa, Shota Yokoyama, Souichi Shiratori, Masao Nakagawa, Ken Kuwahara, Emi Takakuwa, Satoshi Hashino, Takanori Teshima
Antiviral therapy, 27, 5, 13596535221126828, 13596535221126828, Oct. 2022, [International Magazine]
English, Scientific journal, Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral therapy (ART) is not elucidated in acquired immune deficiency syndrome (AIDS) related EBV-SMTs. Here, we report the first successful case of a 29-year-old man with hepatic AIDS related EBV-SMT treated with ART solely. Positron emission tomography scan was useful for the evaluation of disease status. Recent advances in ART that enables to restore patient's immune status rapidly may change the treatment strategy in AIDS related EBV-SMT. - HIV関連悪性リンパ腫の臨床的特徴
遠藤 知之, 後藤 秀樹, 荒 隆英, 長谷川 祐太, 横山 翔大, 高橋 承吾, 米田 和樹, 橋本 大吾, 橋野 聡, 豊嶋 崇徳
日本エイズ学会誌, 24, 1, 13, 20, (一社)日本エイズ学会, Feb. 2022
Japanese - The treatment choices and outcome of hepatocellular carcinoma in hemophilic patients with human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfection due to contaminated blood products in Japan.
Mitsuhisa Takatsuki, Koji Natsuda, Masaaki Hidaka, Koji Sawada, Motohiro Shindo, Tomoyuki Endo, Takeshi Hagiwara, Hiroshi Yotsuyanagi, Tomohiko Koibuchi, Kunihisa Tsukada, Haruka Uemura, Kazuhiko Hayashi, Tomoko Uehira, Eiji Mita, Masahiro Yamamoto, Soichiro Takahama, Susumu Eguchi
Journal of gastrointestinal oncology, 12, 6, 2952, 2959, Dec. 2021, [International Magazine]
English, Scientific journal, BACKGROUND: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection through unheated blood product for hemophilia caused in early 1980s has been significantly serious problem in Japan. After the development of HIV treatment in 1990s, HCV-related hepatocellular carcinoma (HCC) has been one of the most significant problem in these population. Treatment choices for HCC might be limited in hemophilia patients because of their bleeding tendency. The aim of this study was to elucidate the treatment choices and outcome of HCC in hemophilic patients coinfected with HIV/HCV due to contaminated blood products. METHODS: We asked 444 Japanese centers that specialize in treating HIV patients for participation, whether they have HIV/HCV coinfected cases with HCC, and the patient characteristics, treatments for HCC and survival after treatments were retrospectively reviewed according to each institutional medical records. RESULTS: Of 444 centers, 139 centers (31%) responded to the first query, and 8 centers (1.8%) ultimately provided 26 cases of HCC in coinfected hemophilic patients, diagnosed between December 1999 and December 2017. All 26 were male hemophilic patients, with a median age at HCC diagnosis of 49 (range, 34-73) years. Thirteen cases (50%) were HCV-RNA positive, and 14 cases (54%) had a solitary tumor. Even in the cases of Child-Pugh grade A, only 1 case underwent resection, and 18 cases (69%) did not receive the standard treatment recommended by the Japanese Society of Hepatology. CONCLUSIONS: Hemophilic HCC patients with HIV/HCV coinfection may not routinely receive standard treatment due to their bleeding tendency and several complications related to HIV/HCV coinfection. - Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
Takashi Ishio, Sarvesh Kumar, Joji Shimono, Anusara Daenthanasanmak, Sigrid Dubois, Yuquan Lin, Bonita R Bryant, Michael N Petrus, Emmanuel Bachy, Da Wei Huang, Yandan Yang, Patrick L Green, Hiroo Hasegawa, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takashi Yokota, Kanako C Hatanaka, Yutaka Hatanaka, Shinya Tanaka, Yoshihiro Matsuno, Yibin Yang, Satoshi Hashino, Takanori Teshima, Thomas A Waldmann, Louis M Staudt, Masao Nakagawa
Blood, 139, 10, 1541, 1556, 24 Nov. 2021, [International Magazine]
English, Scientific journal, Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy. - E157Q変異を有する未治療HIV-1感染者におけるインテグラーゼ阻害薬をキードラッグとした抗HIV薬開始後の臨床経過
宇野 俊介, 菊地 正, 林田 庸総, 今橋 真弓, 南 留美, 古賀 道子, 寒川 整, 渡邊 大, 藤井 輝久, 健山 正男, 松下 修三, 吉野 友祐, 遠藤 知之, 堀場 昌英, 谷口 俊文, 猪狩 英俊, 吉田 繁, 豊嶋 崇徳, 中島 秀明, 横幕 能行, 岩谷 靖雅, 蜂谷 敦子, 潟永 博之, 吉村 和久, 杉浦 亙
日本エイズ学会誌, 23, 4, 423, 423, (一社)日本エイズ学会, Nov. 2021
Japanese - E157Q変異を有する未治療HIV-1感染者におけるインテグラーゼ阻害薬をキードラッグとした抗HIV薬開始後の臨床経過
宇野 俊介, 菊地 正, 林田 庸総, 今橋 真弓, 南 留美, 古賀 道子, 寒川 整, 渡邊 大, 藤井 輝久, 健山 正男, 松下 修三, 吉野 友祐, 遠藤 知之, 堀場 昌英, 谷口 俊文, 猪狩 英俊, 吉田 繁, 豊嶋 崇徳, 中島 秀明, 横幕 能行, 岩谷 靖雅, 蜂谷 敦子, 潟永 博之, 吉村 和久, 杉浦 亙
日本エイズ学会誌, 23, 4, 423, 423, (一社)日本エイズ学会, Nov. 2021
Japanese - Indications and waiting list priority for deceased donor liver transplantation in HIV/HCV co-infected hemophilic patients in Japan through contaminated blood product.
Susumu Eguchi, Hiroto Egawa, Hidetoshi Eguchi, Tomoko Uehira, Tomoyuki Endo, Takuya Genda, Masahiro Shinoda, Kiyoshi Hasegawa, Tsuyoshi Shimamura, Kunihisa Tsukada, Tetsuya Hara, Kazuhiko Nakao, Hiroshi Yatsuhashi, Hiroshi Yotsuyanagi, Koji Natsuda, Akihiko Soyama, Masaaki Hidaka, Takanobu Hara, Mitsuhisa Takatsuki
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 909, 914, Aug. 2021, [International Magazine]
English, Scientific journal, HIV/HCV co-infection from blood products for hemophilia has been a social problem in Japan. Liver transplantation (LT) is an important treatment option for hepatic failure and cirrhosis of the liver in co-infected patients, and appropriate indications for LT, especially organ form deceased donors, are required by society. The aim is to propose priority status for the waiting list for deceased donor (DD) LT in HIV/HCV co-infected patients in Japan based on medical and scientific considerations. Since 2009, we have been working on the subject in research projects under grants-in-aid for health and labour sciences research on AIDS measures provided by the Ministry of Health, Labour and Welfare (the Kanematsu project and Eguchi project). Our research showed that hepatic fibrosis is advanced in HIV/HCV co-infected Japanese patients, especially those with hemophilia who became infected from blood products at a faster rate than HCV mono-infected patients. In addition, those patients who developed portal hypertension had a poor prognosis at a young age. The results of our research contributed to increasing the priority score of those patients on the deceased donor liver transplantation (DDLT) waiting list in 2013 and to establishing a scoring system for DDLT corresponding to the Model for End-stage Liver disease (MELD) score in 2019. This paper introduces changes in priority and the current state of priority of the DDLT waiting list for HIV/HCV co-infected patients in Japan. - B症状や末梢神経障害を契機に診断された、クリオグロブリン(CG)血管炎の1例
足澤 萌奈美, 大岩 慧, 瀬尾 祥, 田中 大貴, 工藤 彰彦, 阿部 恵, 江口 克紀, 長井 梓, 脇田 雅大, 白井 慎一, 岩田 育子, 松島 理明, 原田 晋平, 遠藤 知之, 矢部 一郎
臨床神経学, 61, 7, 503, 503, (一社)日本神経学会, Jul. 2021
Japanese - High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
Souichi Shiratori, Hiroyuki Ohigashi, Takahide Ara, Atsushi Yasumoto, Hideki Goto, Masao Nakagawa, Junichi Sugita, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima
Annals of hematology, 100, 5, 1321, 1328, May 2021, [International Magazine]
English, Scientific journal, Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 109/L vs 0.06 × 109/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD. - [Emergence of mutation in the colony-stimulating factor 3 receptor gene during follow-up of unclassifiable myeloproliferative neoplasm].
Shinpei Harada, Kohei Okada, Shota Yokoyama, Daisuke Hidaka, Eiko Hayase, Masahiro Onozawa, Hideki Goto, Daigo Hashimoto, Kaoru Kahata, Tomoyuki Endo, Takanori Teshima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 62, 11, 1609, 1614, 2021, [Domestic magazines]
Japanese, Scientific journal, A 25-year-old male with a medical history of stress polycythemia was admitted to a previous hospital for leukocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed left-shifted myeloid hyperplasia without increased blasts and normal male karyotype. No mutations of JAK2, V617F, and colony-stimulating factor 3 receptor gene (CSF3R) were detected. Fluorescence in-situ hybridization for BCR-ABL1 and FIP1L1-PDGFRA were negative. Based on these findings, a diagnosis of an unclassifiable myeloproliferative neoplasm was made, and he was started on hydroxyurea treatment. He was referred to our hospital in April 2016 for transfusion dependence. Bone marrow examination performed at our hospital revealed granulocytic dysplasia and CSF3R T618I was detected. After induction therapy, CSF3R T618I became undetectable, and he went on to undergo allogeneic stem cell transplantation in October 2016. He has been in remission for >4 years posttransplantation. CSF3R T618I is one of the genes responsible for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, suggesting its involvement in the pathogenesis of this case. - Utility of the Rapid Antigen Detection Test E. histolytica Quik Chek for the Diagnosis of Entamoeba histolytica Infection in Nonendemic Situations.
Yasuaki Yanagawa, Rieko Shimogawara, Tomoyuki Endo, Rika Fukushima, Hiroyuki Gatanaga, Kasumi Hayasaka, Yoshimi Kikuchi, Taiichiro Kobayashi, Michiko Koga, Tomohiko Koibuchi, Toshikazu Miyagawa, Ayaka Nagata, Hirotomo Nakata, Shinichi Oka, Risa Otsuka, Kazumi Sakai, Mami Shibuya, Hiroyuki Shingyochi, Etsuko Tsuchihashi, Koji Watanabe, Kenji Yagita
Journal of clinical microbiology, 58, 11, 21 Oct. 2020, [International Magazine]
English, Scientific journal, Entamoeba histolytica infection is an increasingly common sexually transmitted infection in Japan. Currently, stool ova and parasite examination (O&P) is the only approved diagnostic method. Here, we assessed the utility of the commercially available rapid antigen detection test (Quik Chek) for E. histolytica A multicenter cross-sectional study was conducted. Stool samples that had been submitted for O&P were included. The samples were subjected to both Quik Chek and PCR, and the Quik Chek results were assessed in comparison with PCR as the reference standard. E. histolytica infection was confirmed in 5.8% (38/657) of the samples and comprised 20 diarrheal and 18 nondiarrheal cases. The overall sensitivity and specificity of Quik Chek were 44.7% (95% confidence interval, 30.1 to 60.3) and 99.8% (99.1 to 100), respectively. The sensitivity of Quik Chek was higher for diarrheal cases (60.0%) than for nondiarrheal cases (27.8%). Furthermore, the combined use of Quik Chek with O&P increased the sensitivity (78.9%), especially for diarrheal cases (up to 90%). The E. histolytica burden assessed by quantitative PCR was similar between Quik Chek-positive and -negative samples. The Quik Chek assay sensitivity was lower for cyst-containing stools than for trophozoite-containing stools, although it was shown that cultured E. histolytica clinical strains from Quik Chek-negative cyst-containing stools exhibited antigenicity in vitro The present study confirmed the high specificity of Quik Chek for E. histolytica infection. Combined use with O&P increased the sensitivity of detection, facilitating the use of Quik Chek in point-of-care settings in nonendemic situations. - A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Kenshi Suzuki, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Ryota Shiibashi, Koji Izutsu
Cancer science, 111, 9, 3327, 3337, Sep. 2020, [International Magazine]
English, Scientific journal, Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression-free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow-up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug-related atrial fibrillation or hypertension. Although the follow-up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI-173646). - Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.
Hideki Goto, Daisuke Hidaka, Satoshi Yamamoto, Koji Hayasaka, Rie Michimata, Ikuko Kagawa, Kana Sunagoya, Hiroaki Iijima, Eiko Hayase, Souichi Shiratori, Kohei Okada, Junichi Sugita, Masahiro Onozawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Chikara Shimizu, Takanori Teshima
Journal of clinical apheresis, 35, 5, 413, 419, Sep. 2020, [International Magazine]
English, Scientific journal, BACKGROUND: Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma. STUDY DESIGN AND METHODS: Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis. RESULTS: In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation. CONCLUSION: Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells. - Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.
Ichiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, Tohru Kobayashi, Masahide Yamamoto, Akihisa Sawada, Yoshinori Ito, Noriko Fukuhara, Asao Hirose, Yusuke Takeda, Masanori Makita, Tomoyuki Endo, Shun-Ichi Kimura, Masataka Ishimura, Osamu Miura, Shouichi Ohga, Hiroshi Kimura, Shigeyoshi Fujiwara, Ayako Arai
Blood advances, 4, 13, 2918, 2926, 14 Jul. 2020, [International Magazine]
English, Scientific journal, Systemic chronic active Epstein-Barr virus infection (sCAEBV) was defined as a T- or NK-cell neoplasm in the 2017 World Health Organization (WHO) classification. To clarify the clinical features of sCAEBV under this classification and review the effects of chemotherapy, we performed a nationwide survey in Japan from 2016 through 2018 of patients with sCAEBV newly diagnosed from January 2003 through March 2016. One hundred cases were evaluated. The patients were aged 1 to 78 years (median, 21) and included 53 males and 47 females. Spontaneous regression was not observed in patients with active disease. In the childhood-onset group (age, <9 years), 78% of the patients were male. In contrast, 85% of the patients in the elderly-onset group (age, >45 years) were female. The prognosis of the childhood-onset group was better than those of the adolescent/adult- and elderly-onset groups. The main chemotherapies used were a combination of cyclosporine A, steroids, and etoposide (cooling therapy) in 52 cases and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) in 45 cases. The rate of complete response (CR), defined as complete resolution of disease activity, was 17% for cooling therapy and 13% for CHOP. Virological CR was not observed. The 3-year overall survival rates in patients treated with chemotherapy only (n = 20), chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 47), and allo-HSCT only (n = 12) were 0%, 65%, and 82%, respectively. Distinct characteristics were observed between childhood- and elderly-onset sCAEBV, and they appeared to be different disorders. Chemotherapy is currently insufficient to resolve disease activity and eradicate infected cells. The development of an effective treatment is urgently needed. - 未治療又は再発/難治性の原発性マクログロブリン血症患者を対象としたチラブルチニブ(ONO/GS-4059)の国内第II相試験
棟方 理, 関口 直宏, 頼 晋也, 鈴木 憲史, 半田 寛, 柴山 浩彦, 遠藤 知之, 照井 康仁, 岩城 憲子, 福原 規子, 立津 央, 飯田 真介, 石川 隆之, 椎橋 竜太, 伊豆津 宏二
日本リンパ網内系学会会誌, 60, 79, 79, (一社)日本リンパ網内系学会, Jul. 2020
Japanese - The second case of deceased donor liver transplantation in a patient coinfected with HIV and HCV in Japan: Special reference to the management of complicated coagulopathy due to a diverse spectrum of preformed anti-HLA antibodies.
Norio Kawamura, Ryoichi Goto, Yasuyuki Koshizuka, Masaaki Watanabe, Tomomi Suzuki, Tomoyuki Endo, Takeshi Kondo, Akinobu Taketomi, Tsuyoshi Shimamura
Japanese journal of infectious diseases, 73, 5, 369, 372, 30 Apr. 2020, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, We report the second case of deceased donor liver transplantation in a patient co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in Japan. A 48- year-old patient with hemophilia A was infected with HIV and HCV through a contaminated factor VIII concentrate in his childhood and developed cirrhosis and hepatocellular carcinoma. The patient was on the transplant list for a deceased donor liver. The patient had broad spectrum anti-HLA class I and II antibodies, which may have been due to repeated whole blood transfusions in the past. Catastrophic coagulopathy during the surgery was predicted because of the underlying hemophilic status and severe thrombocytopenia requiring HLA-matched platelet products, which are difficult to obtain quickly. To maintain adequate platelet counts(>5x104/ μl) while waiting liver transplantation, a thrombopoietin receptor agonist and rituximab were administered. During surgery, factor VIII concentrate was administered according to the previously planned protocol. Adequate hemostasis was obtained, and the operation was completed without uncontrollable coagulopathy. The postoperative course was uneventful, and the patient was discharged on postoperative day 41. Detailed planning is required for surgical patients with hemophilia and HIV/HCV cirrhosis, especially for those with a diverse spectrum of anti-HLA antibodies. - Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Souichi Shiratori, Hiroyuki Ohigashi, Shuichiro Takahashi, Takahide Ara, Hideki Goto, Masao Nakagawa, Junichi Sugita, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima
Annals of hematology, 99, 3, 591, 598, Mar. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM. - 妊娠後期に診断された発作性夜間ヘモグロビン尿症に対してeculizumabを導入した1例
小島 圭祐, 荒 隆英, 遠藤 知之, 高橋 承吾, 米田 和樹, 横山 翔大, 笠原 耕平, 白鳥 聡一, 後藤 秀樹, 中川 雅夫, 森川 守, 山本 準也, 豊嶋 崇徳
臨床血液, 60, 11, 1583, 1583, (一社)日本血液学会-東京事務局, Nov. 2019
Japanese - ART開始後に縮小傾向を認めたEBV-associated smooth muscle tumor合併AIDSの一例
荒 隆英, 遠藤 知之, 後藤 秀樹, 笠原 耕平, 長谷川 裕太, 横山 翔大, 高桑 恵美, 松野 吉宏, 橋野 聡, 豊嶋 崇徳
日本エイズ学会誌, 21, 4, 426, 426, (一社)日本エイズ学会, Nov. 2019
Japanese - 腸管アメーバ赤痢に対する迅速抗原診断キットの有用性に関する検討(Ameba-Dx研究班)
遠藤 知之, 大塚 梨沙, 鯉渕 智彦, 古賀 道子, 小林 泰一郎, 坂井 和巳, 渋谷 真美, 下河原 理江子, 新行内 裕之, 土橋 悦子, 中田 浩智, 永田 彩夏, 福嶋 理香, 宮川 寿一, 八木田 健司, 柳川 泰昭, 渡辺 恒二, Ameba-Dx Study Group
日本エイズ学会誌, 21, 4, 435, 435, (一社)日本エイズ学会, Nov. 2019
Japanese - HIV感染者のC型慢性肝炎に対するソホスブビルを用いた経口抗HCV療法
四柳 宏, 塚田 訓久, 三田 英治, 遠藤 知之, 潟永 博之, 木村 哲
日本エイズ学会誌, 21, 1, 27, 33, (一社)日本エイズ学会, Feb. 2019
Japanese, 日本人のHIV/HCV重複感染者にソホスブビルの投与を行った際の効果と安全性について検討した。38名(HCV genotype 1:32名、HCV genotype 2:6名)に対しソホスブビルを用いた治療を開始した。すべての症例が中断することなく治療を完遂し、服薬アドヒアランスは100%であった。すべての症例でSVR12が得られ、Fib-4 index、肝硬度とも12週間の治療後に多くの症例で低下しており、肝硬変域から離脱する症例もそれぞれ3例認められた。治療前後のAFP平均値は16.2±27.2ng/mL、4.9±3.3ng/mLであり、ほとんどの症例でAFPの低下が認められた。また、総コレステロール値に関して、Genotype 1での治療前後の平均値は162.9±32.4mg/dL、213.8±54.8mg/dL、genotype 2での治療前後の平均値は183.2±22.2mg/dL、179.0±29.6mg/dLであり、特にgenotype 1の症例で上昇が認められた。治療中の有害事象としてはgenotype 1で感冒様症状2名、そう痒感・皮疹・頭痛・上腹部痛・眼球結膜充血各1名が認められた。また、genotype 2で貧血が1名に認められた。 - Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study
Hidaka D, Onozawa M, Hashiguchi J, Miyashita N, Kasahara K, Fujisawa S, Hayase E, Okada K, Shiratori S, Goto H, Sugita J, Nakagawa M, Hashimoto D, Kahata K, Endo T, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Imai K, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Shimizu C, Kondo T, Teshima T
Clin Transplant, 18, 11, e469, e479, Nov. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-α (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. RESULTS: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. CONCLUSION: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors. - Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources
Ishio T, Sugita J, Tateno T, Hidaka D, Hayase E, Shiratori S, Okada K, Goto H, Onozawa M, Nakagawa M, Hashimoto D, Kahata K, Fujimoto K, Endo T, Kondo T, Teshima T
Biol Blood Marrow Transplant, 24, 10, 1990, 1996, Elsevier BV, Oct. 2018, [Peer-reviewed]
English, Scientific journal - 成人急性リンパ性白血病におけるIKZF1欠失およびCRLF2発現の解析(Analysis of IKZF1 deletion and CRLF2 expression in adult patients with acute lymphoblastic leukemia)
橋口 淳一, 小野澤 真弘, 藤澤 真一, 高橋 秀一郎, 宮下 直洋, 早瀬 英子, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 中川 雅夫, 橋本 大吾, 加畑 馨, 遠藤 知之, 山本 聡, 堤 豊, 長谷山 美仁, 永嶋 貴博, 盛 暁生, 太田 秀一, 宮城島 拓人, 柿木 康孝, 黒澤 光俊, 岩崎 博, 近藤 健, 豊嶋 崇徳
臨床血液, 59, 9, 1648, 1648, (一社)日本血液学会-東京事務局, Sep. 2018
English - The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation
Hidaka D, Hayase E, Shiratori S, Hasegawa Y, Ishio T, Tateno T, Okada K, Goto H, Sugita J, Onozawa M, Nakagawa M, Kahata K, Endo T, Hashimoto D, Teshima T
Clin Transplant, 32, 9, e13361, Sep. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings. - Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy
Nakamura H, Odani T, Yasuda S, Noguchi A, Fujieda Y, Kato M, Oku K, Bohgaki T, Sugita J, Endo T, Teshima T, Atsumi T
Mod Rheumatol, 28, 5, 879, 884, Sep. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, OBJECTIVES: The objective of this study is to elucidate the efficacy and safety of autologous haematopoietic stem cell transplantation (HSCT) for Japanese patients with systemic sclerosis (SSc). METHODS: A phase II clinical trial included SSc patients diagnosed within the last three years having at least one of the following clinical features: diffuse skin sclerosis with modified Rodman total thickness skin score (mRSS) ≥ 15, refractory digital ulcer or interstitial lung disease (ILD). HSCT were performed after conditioning using cyclophosphamide. RESULTS: Fourteen patients were enrolled and underwent HSCT. Median follow-up period was 137 months. Overall survival or event-free survival rate was 93% or 40% at 10 years, respectively. Eight patients (57%) achieved more than a 50% decrease in mRSS from baseline within six months after HSCT. Six patients (43%) required additional immunosuppressive treatments due to progression of diffuse skin sclerosis and/or ILD during follow-up period. Adverse events related to HSCT occurred in six patients (43%). Severe cardiomyopathy occurred in two patients, and one of them had a fatal course. CONCLUSION: HSCT is a feasible treatment bringing favourable results to more than half of our patients with SSc. Careful selection of the patients is essential for whom benefited from HSCT, considering the risk-benefit balance of the treatment. - Disseminated fusariosis emerged from prolonged local genital infection after cord blood transplantation.
Okada K, Endo T, Hashimoto D, Saga T, Ara T, Ogasawara R, Yasumoto A, Ibata M, Takahata M, Shigematsu A, Kondo T, Muraosa Y, Nomura T, Kanno-Okada H, Hashino S, Tanaka S, Kamei K, Teshima T
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 24, 8, 660, 663, Aug. 2018, [Peer-reviewed]
English, Scientific journal - AMLにおけるWT1発現量と染色体・遺伝子異常の関連
日高 大輔, 小野澤 真弘, 橋口 淳一, 宮下 直洋, 笠原 耕平, 藤澤 真一, 早瀬 英子, 岡田 耕平, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 中川 雅夫, 加畑 馨, 橋本 大吾, 遠藤 知之, 山本 聡, 堤 豊, 長谷山 美仁, 永嶋 貴博, 盛 暁生, 太田 秀一, 酒井 基, 石原 敏道, 今井 陽俊, 宮城島 拓人, 柿木 康孝, 黒澤 光俊, 小林 一, 岩崎 博, 清水 力, 近藤 健, 豊嶋 崇徳
臨床血液, 59, 7, 964, 964, (一社)日本血液学会-東京事務局, Jul. 2018
Japanese - Successful endoscopic sphincterotomy for choledocholithiasis in a patient with severe hemophilia A and inhibitors.
Ryo Sugiura, Masaki Kuwatani, Kazumichi Kawakubo, Itsuki Sano, Shin Kato, Tomoyuki Endo, Naoya Sakamoto
Clinical journal of gastroenterology, 11, 3, 188, 192, Jun. 2018, [Domestic magazines]
English, Scientific journal, Endoscopic sphincterotomy (ES) is a standard procedure for bile duct stone removal. However, the safety of ES in patients with hemophilia remains unknown. We treated a 46-year-old man who had choledocholithiasis and severe hemophilia A with high-responding inhibitors during immune tolerance induction therapy. Since coagulation factor VIII inhibitors neutralize and inactivate endogenous and exogenous factor VIII, bleeding risk is higher in hemophilia A patients with inhibitors than in those without inhibitors. With adequate pre- and post-procedure monitoring of the clotting factor and supplemented clotting factor, the patient could safely undergo ES without bleeding complications. ES can be also an effective and safe first-line therapy for choledocholithiasis in patients with hemophilia and inhibitors under the condition of appropriate management. - 担癌患者の精査加療中、偶発的に病理組織診断された慢性リンパ性白血病/リンパ球性リンパ腫の3例
岡田 宏美, 清水 亜衣, 桑原 健, 大塚 拓也, 高桑 恵美, 岡田 耕平, 白鳥 聡一, 遠藤 知之, 豊嶋 崇徳, 三橋 智子, 松野 吉宏
日本リンパ網内系学会会誌, 58, 111, 111, (一社)日本リンパ網内系学会, May 2018
Japanese - 多職種で連携して診療にあたったHIV合併妊娠管理についての検討
金川 明功, 小島 崇史, 山田 崇弘, 長 和俊, 遠藤 知之, 西村 あや子, 石川 聡司, 森川 守, 山田 俊, 近藤 健, 水上 尚典
北海道産科婦人科学会会誌, 62, 1, 219, 220, 北海道産科婦人科学会, Mar. 2018
Japanese - T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation
Shiratori S, Kosugi-Kanaya M, Hayase E, Okada K, Goto H, Sugita J, Onozawa M, Nakagawa M, Kahata K, Hashimoto D, Endo T, Kondo T, Teshima T
Transpl Immunol, 46, 21, 22, Feb. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal - 同種造血幹細胞移植を施行したCSF3R T613I変異陽性非定型慢性骨髄性白血病
原田 晋平, 岡田 耕平, 日高 大輔, 早瀬 英子, 後藤 秀樹, 橋本 大吾, 加畑 馨, 遠藤 知之, 豊嶋 崇徳
臨床血液, 58, 11, 2299, 2299, (一社)日本血液学会-東京事務局, Nov. 2017
Japanese - IgA型ALアミロイドーシスに線状IgA皮膚症を併発した1例
山口 泰之, 氏家 英之, 大東 寛幸, 岩田 浩明, 村松 憲, 清水 宏, 遠藤 知之, 豊嶋 崇徳
日本皮膚科学会雑誌, 127, 9, 2111, 2111, (公社)日本皮膚科学会, Aug. 2017
Japanese - 北海道HIV福祉サービスネットワークの構築
富田 健一, 白坂 るみ, 遠藤 知之, 渡部 恵子, 武内 阿味, 坂本 玲子, センテノ田村 恵子, 石田 陽子, 豊嶋 崇徳
日本エイズ学会誌, 19, 3, 180, 184, (一社)日本エイズ学会, Aug. 2017
Japanese, HIV陽性者に困難なく福祉サービス提供を行うために、「北海道福祉サービスネットワーク」を構築し、有効な手段を検討した。対象施設は、北海道内の福祉事業所(高齢者領域のサービス事業所、障がい領域のサービス事業所、領域を問わずサービス提供を行う保険外の事業所)とした。北海道ブロック各拠点病院HIV担当ソーシャルワーカーが、HIV陽性者に対して理解があると感じられる福祉事業所に登録依頼を行った。その結果、407件の登録が得られ、HIV陽性者へのサービス提供の経験のある福祉事業所の登録割合が92.3%と最も高かった。これは、サービス提供を行うことで、それまで未知であったHIV感染者に対する漠然とした不安や戸惑いが払拭されたものと考えられた。一方、登録を断った事業所については、施設長・責任者の賛同が得らないことを理由にあげられることから、施設長や責任者に対して、HIVに関する正しい知識を説明するなど、直接的にアプローチすることが有効と考えた。行政(北海道保健福祉部)から、ネットワークへの登録依頼文書を配布した987法人からは、2週間以内に17件の社会福祉法人、87件の福祉事業所からの登録が得られた。2週間という短期間で、多くの登録を得られたことは、行政との連携がきわめて有効と考えられた。 - Phase II study of intrabone single unit cord blood transplantation for hematological malignancies
Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida
CANCER SCIENCE, 108, 8, 1634, 1639, Aug. 2017, [Peer-reviewed]
English, Scientific journal - Diffuse large B-cell lymphoma with a bulky mass in the cranial vault
Minoru Kanaya, Tomoyuki Endo, Daigo Hashimoto, Shogo Endo, Ryo Takemura, Kohei Okada, Kanako C. Hatanaka, Yoshihiro Matsuno, Takanori Teshima
INTERNATIONAL JOURNAL OF HEMATOLOGY, 106, 2, 147, 148, Aug. 2017, [Peer-reviewed]
English - Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
Takahiro Tateno, Masahiro Onozawa, Junichi Hashiguchi, Takashi Ishio, Sayaka Yuzawa, Satomi Matsuoka, Mizuha Kosugi-Kanaya, Kohei Okada, Souichi Shiratori, Hideki Goto, Taichi Kimura, Junichi Sugita, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Shinya Tanaka, Satoshi Hashino, Takanori Teshima
TRANSPLANT INFECTIOUS DISEASE, 19, 4, Aug. 2017, [Peer-reviewed]
English, Scientific journal - Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.
Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida
Cancer science, 108, 8, 1634, 1639, Aug. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal, The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR ≥4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 × 107 /kg (range, 2.0-4.9 × 107 /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils ≥0.5 × 109 /L, reticulocytes ≥1%, and platelets ≥20 × 109 /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865. - Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
Naohiro Miyashita, Tomoyuki Endo, Masahiro Onozawa, Daigo Hashimoto, Takeshi Kondo, Katsuya Fujimoto, Kaoru Kahata, Junichi Sugita, Hideki Goto, Toshihiro Matsukawa, Satoshi Hashino, Takanori Teshima
TRANSPLANT INFECTIOUS DISEASE, 19, 3, Jun. 2017, [Peer-reviewed]
English, Scientific journal - MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase
M. Kanaya, Y. Hayashi, D. Hashimoto, T. Endo, J. Sugita, H. Ohigashi, J. Hashiguchi, T. Matsukawa, S. Matsuoka, M. Kosugi-Kanaya, H. Goto, M. Onozawa, K. Kahata, K. Fujimoto, T. Kondo, K. Akizawa, H. Shibuya, C. Shimizu, T. Teshima
BONE MARROW TRANSPLANTATION, 52, 5, 778, 780, May 2017, [Peer-reviewed]
English, Scientific journal - Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD
Toshihiro Matsukawa, Daigo Hashimoto, Junichi Sugita, Seitarou Nakazawa, Takae Matsushita, Haruhiko Kashiwazaki, Hideki Goto, Masahiro Onozawa, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Yutaka Yamazaki, Takanori Teshima
INTERNATIONAL JOURNAL OF HEMATOLOGY, 104, 1, 117, 124, Jul. 2016, [Peer-reviewed]
English, Scientific journal - Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome
Souichi Shiratori, Katsuya Fujimoto, Machiko Nishimura, Kanako C. Hatanaka, Mizuha Kosugi-Kanaya, Kohei Okada, Junichi Sugita, Akio Shigematsu, Daigo Hashimoto, Tomoyuki Endo, Takeshi Kondo, Riichiro Abe, Satoshi Hashino, Yoshihiro Matsuno, Hiroshi Shimizu, Takanori Teshima
HEMATOLOGICAL ONCOLOGY, 34, 1, 9, 16, Mar. 2016, [Peer-reviewed]
English, Scientific journal - 血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 HCV/HIV重複感染血友病患者に対する脳死肝移植時の止血管理
遠藤知之, 嶋村剛, 後藤了一, 藤本勝也
血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書, 9‐11, 2016
Japanese - 血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 脳死肝移植待機中のHIV/HCV重複感染による肝硬変2症例に対する術前準備
嶋村剛, 遠藤知之, 後藤了一
血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書, 21‐22, 2016
Japanese - Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy.
Kasahara K, Onozawa M, Miyashita N, Yokohata E, Yoshida M, Kanaya M, Kosugi-Kanaya M, Takemura R, Takahashi S, Sugita J, Shigematsu A, Takahata M, Fujisawa S, Hashimoto D, Fujimoto K, Endo T, Kondo T, Teshima T
Case reports in hematology, 2016, 2373902, 5, Hindawi Limited, 2016, [Peer-reviewed]
Scientific journal, We report a case of acute myeloid leukemia (AML) with two cytogenetically unrelated clones. The patient was a 45-year-old male who was diagnosed with acute monoblastic leukemia (AMoL). Initial G-band analysis showed 51,XY,+6,+8,inv(9)(p12q13)c,+11,+13,+19[12]/52,idem,+Y[8], but G-band analysis after induction therapy showed 45,XY,-7,inv(9)(p12q13)c[19]/46,XY,inv(9)(p12q13)c[1]. Retrospective FISH analysis revealed a cryptic monosomy 7 clone in the initial AML sample. The clone with multiple trisomies was eliminated after induction therapy and never recurred, but a clone with monosomy 7 was still detected in myelodysplastic marrow with a normal blast percentage. Both clones were successfully eliminated after related peripheral blood stem cell transplantation, but the patient died of relapsed AML with monosomy 7. We concluded that one clone was de novo AMoL with chromosome 6, 8, 11, 13, and 19 trisomy and that the other was acute myeloid leukemia with myelodysplasia-related changes - Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation.
Yuki Tazawa, Akio Shigematsu, Kumiko Kasashi, Junichi Sugita, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima, Ken Iseki, Mitsuru Sugawara, Yoh Takekuma
Journal of pharmaceutical health care and sciences, 2, 18, 18, 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between Cmax and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved. - Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration
Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T
Transpl Infect Dis., 17, 6, 810, 815, Dec. 2015, [Peer-reviewed] - Ultrasonographic evaluation of gastrointestinal graft-versus-host disease after hematopoietic stem cell transplantation
Mutsumi Nishida, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Tatsunori Horie, Takahito Iwai, Tomoyuki Endo, Akihiro Iguchi, Hitoshi Shibuya, Kanako Hatanaka, Chikara Shimizu, Takanori Teshima
CLINICAL TRANSPLANTATION, 29, 8, 697, 704, Aug. 2015, [Peer-reviewed]
English, Scientific journal - Erythema annulare centrifugum-like mycosis fungoides after unrelated bone marrow transplantation.
Keisuke Imafuku, Yukiko Nomura, Chihiro Nakayama, Riichiro Abe, Tomoyuki Endo, Hiroshi Shimizu
British journal of haematology, 170, 2, 140, 140, Jul. 2015, [Peer-reviewed], [International Magazine]
English, Scientific journal - Flunarizine Exhibits In Vitro Efficacy Against Lymphoma and Multiple Myeloma Cells
Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Sabine Blaum-Feder, Tomoyuki Endo, Ingo G. H. Schmidt-Wolf
ANTICANCER RESEARCH, 35, 3, 1369, 1376, Mar. 2015, [Peer-reviewed]
English, Scientific journal - In Vitro Efficacy of Cinnarizine Against Lymphoma and Multiple Myeloma
Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Sabine Blaum-Feder, Tomoyuki Endo, Ingo G. H. Schmidt-Wolf
ANTICANCER RESEARCH, 35, 2, 835, 841, Feb. 2015, [Peer-reviewed]
English, Scientific journal - Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma
Souichi Shiratori, Mizuha Kosugi-Kanaya, Akio Shigematsu, Hajime Kobayashi, Satoshi Yamamoto, Naoki Kobayashi, Hiroshi Iwasaki, Akio Mori, Yasuyuki Kunieda, Yutaka Tsutsumi, Mitsutoshi Kurosawa, Yasutaka Kakinoki, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Takanori Teshima
LEUKEMIA & LYMPHOMA, 56, 9, 2592, 2597, 2015, [Peer-reviewed]
English, Scientific journal - Human Herpesvirus-6 Pneumonitis around the Engraftment of Cord Blood Transplantation following Foscarnet Prophylaxis in a Patient with Acute Leukemia.
Ishio T, Endo T, Okada K, Shigematsu A, Hashino S, Teshima T
Case reports in hematology, 2015, 949265, 5, Hindawi Limited, 2015, [Peer-reviewed]
Scientific journal, Human herpesvirus-6 (HHV-6) reactivation is sometimes observed in immunocompromised patients, especially after allogeneic stem cell transplantation. The complications of HHV-6 reactivation in this setting are mainly recognized as HHV-6 encephalitis. We herein report the case of a patient who developed HHV-6 pneumonitis after cord blood transplantation (CBT). A 35-year-old male underwent CBT for T-cell/myeloid mixed phenotype acute leukemia and achieved neutrophil engraftment on day 31. He had received foscarnet as prophylaxis for HHV-6 reactivation. A computed tomography (CT) scan to evaluate the leukemic tumor showed bilateral interstitial pneumonitis on day 33, although he had no respiratory symptoms. The findings of the CT scan were consistent with those of HHV-6 pneumonitis that were reported previously. HHV-6 DNA, but no other pathogens, was detected in his bronchoalveolar lavage (BAL) fluid. The patient was successfully treated with a therapeutic dose of foscarnet. This case indicates that performing a CT scan around the time of neutrophil engraftment can play an important role in detecting the early phase of HHV-6 pneumonia, and BAL should be considered if features consistent with HHV-6 pneumonitis are observed in patients with a risk of HHV-6 reactivation. - CD4/CD8 Double-negative T-cell Lymphoma: A Variant of Primary Cutaneous CD8(+) Aggressive Epidermotropic Cytotoxic T-cell Lymphoma?
Toshinari Miyauchi, Riichiro Abe, Yusuke Morita, Maki Adachi, Keiko Shiba, Yohei Hamade, Nan Saito, Machiko Nishimura, Makoto Ibata, Kohei Okada, Akio Shigematsu, Tomoyuki Endo, Kazuhiro Kawai, Takanori Teshima, Hiroshi Shimizu
ACTA DERMATO-VENEREOLOGICA, 95, 8, 1024, 1025, 2015, [Peer-reviewed]
English - Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection
Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T
Transpl Infect Dis, 16, 5, 797, 801, Oct. 2014, [Peer-reviewed] - Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience
Souichi Shiratori, Kentaro Wakasa, Kohei Okada, Junichi Sugita, Koji Akizawa, Akio Shigematsu, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Chikara Shimizu, Satoshi Hashino, Takanori Teshima
CLINICAL TRANSPLANTATION, 28, 6, 656, 661, Jun. 2014, [Peer-reviewed]
English, Scientific journal - Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation
Yusuke Shono, Souichi Shiratori, Mizuha Kosugi-Kanaya, Satoshi Ueha, Junichi Sugita, Akio Shigematsu, Takeshi Kondo, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Mitsufumi Nishio, Satoshi Hashino, Yoshihiro Matsuno, Kouji Matsushima, Junji Tanaka, Masahiro Imamura, Takanori Teshima
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, 4, 495, 500, Apr. 2014, [Peer-reviewed]
English, Scientific journal - Targeting the Wnt/beta-catenin pathway in multiple myeloma
Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Tomoyuki Endo, Desheng Lu, Ingo G. H. Schmidt-Wolf
Anticancer Research, 33, 11, 4719, 4726, Nov. 2013, [Peer-reviewed]
English, Scientific journal - Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: A randomized multicenter trial
Takeshi Nishijima, Misao Takano, Michiyo Ishisaka, Hirokazu Komatsu, Hiroyuki Gatanaga, Yoshimi Kikuchi, Tomoyuki Endo, Masahide Horiba, Satoru Kaneda, Hideki Uchiumi, Tomohiko Koibuchi, Toshio Naito, Masaki Yoshida, Natsuo Tachikawa, Mikio Ueda, Yoshiyuki Yokomaku, Teruhisa Fujii, Satoshi Higasa, Kiyonori Takada, Masahiro Yamamoto, Shuzo Matsushita, Masao Tateyama, Yoshinari Tanabe, Hiroaki Mitsuya, Shinichi Oka
Internal Medicine, 52, 7, 735, 744, 2013, [Peer-reviewed]
English, Scientific journal - Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Takeshi Nishijima, Hiroyuki Gatanaga, Takuro Shimbo, Hirokazu Komatsu, Tomoyuki Endo, Masahide Horiba, Michiko Koga, Toshio Naito, Ichiro Itoda, Masanori Tei, Teruhisa Fujii, Kiyonori Takada, Masahiro Yamamoto, Toshikazu Miyakawa, Yoshinari Tanabe, Hiroaki Mitsuya, Shinichi Oka
PloS one, 8, 8, e73639, 2013, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Whether tenofovir nephrotoxicity is reversible after its withdrawal is unknown. Furthermore, there are no data on the viral efficacy of raltegravir (RAL) plus ritonavir-boosted Darunavir (DRV/r) in patients with suppressed viral load. METHODS: This multicenter, randomized trial compared renal function and viral efficacy in patients with suppressed viral load treated with RAL+DRV/r and ritonavir-boosted lopinavir (LPV/r) plus tenofovir/emtricitabine (TVD), who had been previously on LPV/r+TVD. The primary endpoint was the proportion of patients with >10% improvement in estimated glomerular filtration rate (eGFR) at 48 weeks calculated with Cockcroft-Gault equation. RESULTS: 58 randomized and treatment-exposed patients were analyzed (28 on RAL+DRV/r and 30 on LPV/r+TVD). Greater than 10% improvement in eGFR was noted in 6 (25%) out of 24 with RAL+DRV/r and 3 (11%) of 28 with LPV/r+TVD, and the difference was not statistically significant (p=0.272, 95% CI -0.067 to 0.354). Sensitivity analyses using three other equations for eGFR showed the same results. Urinary β2 microglobulin, a sensitive marker of tenofovir tubulopathy, significantly improved with RAL+DRV/r than with LPV/r+TVD (-271 versus -64 µg/gCr, p=0.026). Per protocol analysis showed that the HIV-RNA was <50 copies/mL at week 48 in all patients of both arms (24 in RAL+DRV and 29 in LPV/r+TVD). CONCLUSIONS: Switching LPV/r+TVD to RAL+DRV/r did not significantly increase the proportion of patients who showed >10% improvement in renal function among those with relatively preserved eGFR. However, the switch improved urinary β2 microglobulin, suggesting that discontinuation of TDF might be beneficial in the long-term. RAL+DRV/r showed favorable viral efficacy in patients with suppressed viral load. TRIAL REGISTRATION: ClinicalTrials.gov NCT01294761 http://clinicaltrials.gov/ct2/show/NCT01294761?term=SPARE&rank=2, Umin Clinical Trials Registry UMIN000005116 http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000006083&language=J). - 特発性血小板減少性紫斑病治療におけるセファランチン大量療法の有用性 後方視的多施設共同研究
高畑 むつみ, 橋野 聡, 藤本 勝也, 遠藤 知之, 小林 直樹, 黒澤 光俊, 岩崎 博, 三宅 高義, 幸田 久平, 前川 勲, 笹川 裕, 堤 豊, 宮城島 拓人, 田中 淳司, 今村 雅寛, 豊嶋 崇徳
臨床血液, 53, 12, 1983, 1990, (一社)日本血液学会-東京事務局, Dec. 2012
Japanese - [Clinical efficacy of high-dose cepharanthine for idiopathic thrombocytopenic purpura: retrospective multicenter analysis].
Takahata M, Hashino S, Fujimoto K, Endo T, Kobayashi N, Kurosawa M, Iwasaki H, Miyake T, Kohda K, Maekawa I, Sasagawa H, Tsustumi Y, Miyagishima T, Tanaka J, Imamura M, Teshima T
[Rinsho ketsueki] The Japanese journal of clinical hematology, 53, 12, 1983, 1990, Dec. 2012, [Peer-reviewed] - A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens
Haruhiko Kashiwazaki, Takae Matsushita, Junichi Sugita, Akio Shigematsu, Kumiko Kasashi, Yutaka Yamazaki, Takashi Kanehira, Takeshi Kondo, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Masahiro Imamura, Yoshimasa Kitagawa, Nobuo Inoue
SUPPORTIVE CARE IN CANCER, 20, 5, 933, 939, May 2012, [Peer-reviewed]
English, Scientific journal - In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma
Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
LEUKEMIA RESEARCH, 36, 5, 598, 600, May 2012, [Peer-reviewed]
English, Scientific journal - Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation
Haruhiko Kashiwazaki, Takae Matsushita, Junichi Sugita, Akio Shigematsu, Kumiko Kasashi, Yutaka Yamazaki, Takashi Kanehira, Satoshi Yamamoto, Takeshi Kondo, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Masahiro Imamura, Yoshimasa Kitagawa, Nobuo Inoue
SUPPORTIVE CARE IN CANCER, 20, 2, 367, 373, Feb. 2012, [Peer-reviewed]
English, Scientific journal - A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations
Toshihiro Matsukawa, Hideki Goto, Kenta Takahashi, Shinsuke Asanuma, Atsushi Yasumoto, Mutsumi Takahata, Akio Shigematsu, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Shinya Tanaka, Masahiro Imamura
INTERNATIONAL JOURNAL OF HEMATOLOGY, 95, 2, 217, 222, Feb. 2012, [Peer-reviewed]
English, Scientific journal - Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD
Sugita Junichi, Matsushita Takae, Kashiwazaki Haruhiko, Kosugi Mizuha, Takahashi Shojiro, Wakasa Kentaro, Shiratori Souichi, Ibata Makoto, Shono Yusuke, Shigematsu Akio, Obara Masato, Fujimoto Katsuya, Endo Tomoyuki, Nishio Mitsufumi, Kondo Takeshi, Hashino Satoshi, Tanaka Junji, Asaka Masahiro, Imamura Masahiro
Bone Marrow Transplantation, 47, 2, 258, 264, Nature Publishing Group, Feb. 2012
English, Since the safety of folinic acid administration and its efficacy for reducing the toxicity of methotrexate (MTX) remain controversial, we assessed the effect of folinic acid administration after MTX treatment for GVHD prophylaxis on the incidence of oral mucositis and acute GVHD. We retrospectively analyzed data for 118 patients who had undergone allogeneic hematopoietic stem cell transplantation and had received MTX for GVHD prophylaxis. Multivariate analysis showed that systemic folinic acid administration significantly reduced the incidence of severe oral mucositis (OR = 0.13, 95%CI 0.04-0.73, P = 0.014). There was also a tendency for lower incidence of severe oral mucositis in patients who received folinic acid mouthwash (OR = 0.39, 95%CI 0.15-1.00, P = 0.051). No significant difference was observed in the incidence of acute GVHD between patients who received systemic folinic acid administration and those who did not (P = 0.88). Systemic folinic acid administration and mouthwash appear to be useful for reducing the incidence of severe oral mucositis in patients who have received allogeneic hematopoietic mucositis in patients who have received allogeneic hematopoietic stem cell transplantation using MTX as GVHD prophylaxis. - Targeting the Wnt/Beta-catenin Pathway with the Antifungal Agent Ciclopirox Olamine in a Murine Myeloma Model
Young Kim, Matthias Schmidt, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
IN VIVO, 25, 6, 887, 893, Nov. 2011, [Peer-reviewed]
English, Scientific journal - Sustained trilineage hematopoietic recovery in a patient with refractory anemia, del(13)(q12q22), and paroxysmal nocturnal hemoglobinuria-type cells treated with immunosuppressive therapy
Ikumi Kasahara, Mitsufumi Nishio, Tomoyuki Endo, Katsuya Fujimoto, Takao Koike, Naomi Sugimori, Takamasa Katagiri, Shinji Nakao
LEUKEMIA RESEARCH, 35, 9, E147, E148, Sep. 2011, [Peer-reviewed]
English - In vivo efficacy of griseofulvin against multiple myeloma
Young Kim, Petra Alpmann, Sabine Blaum-Feder, Simon Kraemer, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
LEUKEMIA RESEARCH, 35, 8, 1070, 1073, Aug. 2011, [Peer-reviewed]
English, Scientific journal - Increased In vivo Efficacy of Lenalidomide and Thalidomide by Addition of Ethacrynic Acid
Matthias Schmidt, Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
IN VIVO, 25, 3, 325, 333, May 2011, [Peer-reviewed]
English, Scientific journal - The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion
Masahiro Onozawa, Kazumasa Ohmura, Makoto Ibata, Junko Iwasaki, Kohei Okada, Ikumi Kasahara, Keisuke Yamaguchi, Kanako Kubota, Shinichi Fujisawa, Akio Shigematsu, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Junji Tanaka, Yoshihiro Matsuno, Masahiro Asaka, Masahiro Imamura
EUROPEAN JOURNAL OF HAEMATOLOGY, 86, 4, 347, 349, Apr. 2011, [Peer-reviewed]
English - [Successful combination therapy by meropenem and colistin for multi-drug-resistant Pseudomonas aeruginosa infection after allogeneic bone marrow transplantation].
Kanda M, Shigematsu A, Okada K, Kasahara I, Iwasaki J, Yamaguchi K, Onozawa M, Endo T, Akizawa K, Ishiguro N, Hashino S, Imamura M
[Rinsho ketsueki] The Japanese journal of clinical hematology, 52, 3, 118, 123, 3, Mar. 2011, [Peer-reviewed]
Japanese - Influencing the Wnt Signaling Pathway in Multiple Myeloma
Young Kim, Guido Reifenberger, Desheng Lu, Tomoyuki Endo, Dennis A. Carson, Sanna-Marie Gast, Karoline Meschenmoser, Michael Nowak, Ingo G. H. Schmidt-Wolf
ANTICANCER RESEARCH, 31, 2, 725, 730, Feb. 2011, [Peer-reviewed]
English - Increased In Vivo Efficacy of Lenalidomide by Addition of Piroctone Olamine
Young Kim, Petra Alpmann, Sabine Blaum-Feder, Simon Kraemer, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
IN VIVO, 25, 1, 99, 103, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.
Shigematsu A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Yamaguchi K, Wakasa K, Takahata M, Goto H, Ito S, Takemura R, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M
Transplant infectious disease : an official journal of the Transplantation Society, 12, 5, 412, 420, Oct. 2010, [Peer-reviewed], [International Magazine]
English, Scientific journal, Although bacterial infection is a major cause of death even after reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), little is known about the epidemiology and risk factors. The incidence of bacterial infection in 43 patients who received allogeneic bone marrow transplantation (BMT) using a RIC regimen was compared with that in 68 patients who received BMT using a myeloablative conditioning regimen, and risk factors for bacterial infection were identified. Before engraftment, incidences of febrile neutropenia (FN) and documented infections (DI) were significantly decreased in RIC patients (FN: 59.5% vs. 89.6%, P<0.01, DI: 4.8% vs. 17.9%, P<0.01). However, incidence of bacterial infection was significantly increased in RIC patients in the post-engraftment phase (53.8% vs. 11.1%, log-rank, P<0.01). Blood stream was the most frequent focus of infection in both groups. In multivariate analysis, RIC and acute graft-versus-host disease were revealed to be significant risk factors for bacterial infection in this phase. In summary, risk of bacterial infection after engraftment was significantly higher in RIC patients, although infection was decreased before engraftment, and we need to develop a RIC-specific strategy against bacterial infection after RIC SCT. - Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): Clinical efficacy in high-risk patients
Mutsumi Takahata, Satoshi Hashino, Kohei Okada, Masahiro Onozawa, Kaoru Kahata, Junichi Sugita, Akio Shigematsu, Takeshi Kondo, Satoshi Yamamoto, Tomoyuki Endo, Mitsufumi Nishio, Yoichi M. Ito, Junji Tanaka, Takao Koike, Masahiro Asaka, Masahiro Imamura
AMERICAN JOURNAL OF HEMATOLOGY, 85, 4, 243, 248, Apr. 2010, [Peer-reviewed]
English, Scientific journal - DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma
Lei Wang, Hiroshi Nishihara, Taichi Kimura, Yasutaka Kato, Mishie Tanino, Mitsufumi Nishio, Masato Obara, Tomoyuki Endo, Takao Koike, Shinya Tanaka
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 395, 1, 111, 115, Apr. 2010, [Peer-reviewed]
English, Scientific journal - Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation
Takeshi Kondo, Atsushi Yasumoto, Kotaro Arita, Jun-ichi Sugita, Akio Shigematsu, Kohei Okada, Mutsumi Takahata, Masahiro Onozawa, Kaoru Kahata, Yukari Takeda, Masato Obara, Satoshi Yamamoto, Tomoyuki Endo, Mitsufumi Nishio, Norihiro Sato, Junji Tanaka, Satoshi Hashino, Takao Koike, Masahiro Asaka, Masahiro Imamura
INTERNATIONAL JOURNAL OF HEMATOLOGY, 91, 2, 310, 321, Mar. 2010, [Peer-reviewed]
English, Scientific journal - Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier
Katsuya Fujimoto, Tomoyuki Endo, Mitsufumi Nishio, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike
INTERNATIONAL JOURNAL OF HEMATOLOGY, 90, 5, 601, 604, Dec. 2009, [Peer-reviewed]
English, Scientific journal - Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/beta-Catenin Pathway
Desheng Lu, Jerry X. Liu, Tomoyuki Endo, Haowen Zhou, Shiyin Yao, Karl Willert, Ingo G. H. Schmidt-Wolf, Thomas J. Kipps, Dennis A. Carson
PLOS ONE, 4, 12, e8294, Dec. 2009, [Peer-reviewed]
English, Scientific journal - Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib
Ikumi Kasahara, Mitsufumi Nishio, Satoshi Yamamoto, Tomoyuki Endo, Katsuya Fujimoto, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Norihiro Sato, Takao Koike
INTERNATIONAL JOURNAL OF HEMATOLOGY, 90, 3, 413, 415, Oct. 2009, [Peer-reviewed]
English, Scientific journal - Case Report: Clearance of Hepatitis C Virus After Changing the HAART Regimen in a Patient Infected With Hepatitis C Virus and the Human Immunodeficiency Virus
Tomoyuki Endo, Katsuya Fujimoto, Mitsufumi Nishio, Satoshi Yamamoto, Masato Obara, Norihiro Sato, Takao Koike
JOURNAL OF MEDICAL VIROLOGY, 81, 6, 979, 982, Jun. 2009, [Peer-reviewed]
English, Scientific journal - Regimen-Related Mucosal Injury of the Gut Increased the Incidence of CMV Disease after Allogeneic Bone Marrow Transplantation
Akio Shigematsu, Atsushi Yasumoto, Satoshi Yamamoto, Junichi Sugita, Takeshi Kondo, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Shuichi Ota, Norihiro Sato, Mutsumi Takahata, Kohei Okada, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Takao Koike, Masahiro Asaka, Masahiro Imamura
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15, 6, 679, 685, Jun. 2009, [Peer-reviewed]
English, Scientific journal - Targeting Wnt pathway in lymphoma and myeloma cells
Matthias Schmidt, Elisabeth Sievers, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
BRITISH JOURNAL OF HAEMATOLOGY, 144, 5, 796, 798, Mar. 2009, [Peer-reviewed]
English - FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation
Mitsufumi Nishio, Tomoyuki Endo, Katsuya Fujimoto, Satoshi Yamamoto, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 82, 2, 143, 147, Feb. 2009, [Peer-reviewed]
English, Scientific journal - Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia
Akio Shigematsu, Takeshi Kondo, Satoshi Yamamoto, Junichi Sugita, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Soichi Shiratori, Shuichi Ota, Masato Ohara, Kentaro Wakasa, Mutsumi Takahata, Yukari Takeda, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Takao Koike, Masahiro Asaka, Masahiro Imamura
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 5, 568, 575, May 2008, [Peer-reviewed]
English, Scientific journal - 臨床症状を伴った心へのinvolvementを契機として発見された、diffuse large B-cell lymphomaの2例
山田 洋介, 久保田 佳奈子, 遠藤 知之, 中田 匡信, ヘールナンデス 真子, 伊藤 智雄, 松野 吉宏
日本リンパ網内系学会会誌, 48, 77, 77, (一社)日本リンパ網内系学会, May 2008, [Peer-reviewed]
Japanese - Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda, Liguang Chen, Tomoyuki Endo, Li Tang, Desheng Lu, Jariuario E. Castro, George F. Widhopf, Laura Z. Rassenti, Mark J. Cantwell, Charles E. Prussak, Dennis A. Carson, Thomas J. Kipps
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105, 8, 3047, 3052, Feb. 2008, [Peer-reviewed]
English, Scientific journal - A novel strategy for the treatment of acute graft-versus-host disease: removal of excessive inflammatory cytokines using the adsorbent
Takami A, Teshima T, Ushizaki K, Taniguchi T, Endo T, Sakurai H, Nakao S
BONE MARROW TRANSPLANTATION, 41, 1, S229, 2008, [Peer-reviewed]
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, ITALY, MAR 30-APR 02, 2008 - Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation
Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Tomoyuki Endo, Toshiya Sakai, Masato Obara, Kohki Kumano, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Norihiro Sato, Kazuki Koizumi, Masaya Mukai, Takao Koike
BRITISH JOURNAL OF HAEMATOLOGY, 137, 4, 349, 354, May 2007, [Peer-reviewed]
English, Scientific journal - Erratum to "Multiple myeloma associated with sialyl salivary-type amylase" [Clinica Chimica Acta 376 (2007) 121-125] (DOI:10.1016/j.cca.2006.08.002)
Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura
Clinica Chimica Acta, 380, 1-2, 254, 01 May 2007, [Peer-reviewed]
English, Scientific journal - Multiple myeloma associated with sialyl salivary-type amylase
Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura
CLINICA CHIMICA ACTA, 376, 1-2, 121, 125, Feb. 2007, [Peer-reviewed]
English, Scientific journal - BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappa B pathway
Tomoyuki Endo, Mitsufumi Nishio, Thomas Enzler, Howard B. Cottam, Tetsuya Fukuda, Danelle F. James, Michael Karin, Thomas J. Kipps
BLOOD, 109, 2, 703, 710, Jan. 2007, [Peer-reviewed]
English, Scientific journal - Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma
Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Tomoyuki Endo, Toshiya Sakai, Masato Obara, Kohki Kumano, Koichiro Minauchi, Keisuke Yamaguchi, Yukari Takeda, Norihiro Sato, Kazuki Koizumi, Masaya Mukai, Takao Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 77, 3, 226, 232, Sep. 2006, [Peer-reviewed]
English, Scientific journal - Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy
T Hashimoto, M Nishio, T Sakai, K Fujimoto, N Sato, T Endo, T Koike
CLINICAL INFECTIOUS DISEASES, 42, 11, 1653, 1655, Jun. 2006, [Peer-reviewed]
English - Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia
M Nishio, T Endo, K Fujimoto, N Sato, T Sakai, M Obara, K Kumano, K Minauchi, T Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 75, 6, 527, 529, Dec. 2005, [Peer-reviewed]
English - Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation
A Takami, H Okumura, H Yamazaki, M Kami, SW Kim, H Asakura, T Endo, M Nishio, K Minauchi, K Kumano, N Sugimori, S Mori, Y Takemoto, S Shimadoi, J Ozaki, Y Takaue, S Nakao
INTERNATIONAL JOURNAL OF HEMATOLOGY, 82, 5, 449, 455, Dec. 2005, [Peer-reviewed]
English, Scientific journal - Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1 alpha
M Nishio, T Endo, N Tsukada, J Ohata, S Kitada, JC Reed, NJ Zvaifler, TJ Kipps
BLOOD, 106, 3, 1012, 1020, Aug. 2005, [Peer-reviewed]
English, Scientific journal - Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma
H Goto, M Nishio, T Endo, N Sato, K Koizumi, K Fujimoto, T Sakai, K Kumano, M Obara, T Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 74, 6, 526, 528, Jun. 2005, [Peer-reviewed]
English, Scientific journal - Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS
T Nomura, R Abe, K Fujimoto, T Endo, H Shimizu, T Koike
AIDS, 18, 18, 2446, 2448, Dec. 2004, [Peer-reviewed]
English - A preliminary analysis of the balance between Th1 and Th2 cells after CD34(+) cell-selected autologous PBSC transplantation
T Endo, N Sato, K Koizumi, M Nishio, K Fujimoto, S Yamamoto, T Sakai, T Bohgaki, K Sawada, T Koike
CYTOTHERAPY, 6, 4, 337, 343, Aug. 2004, [Peer-reviewed]
English, Scientific journal - Localized relapse in bone marrow of extremities after allogeneic stem cell transplantation for acute lymphoblastic leukemia
T Endo, N Sato, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, K Minauchi, T Koike
AMERICAN JOURNAL OF HEMATOLOGY, 76, 3, 279, 282, Jul. 2004, [Peer-reviewed]
English, Scientific journal - Codevelopment of dendritic cells along with erythroid differentiation from human CD34(+) cells by tumor necrosis factor-alpha
H Fukaya, WG Xiao, K Inaba, Y Suzuki, M Hirokawa, Y Kawabata, A Komatsuda, T Endo, H Kishimoto, G Takada, K Sawada
EXPERIMENTAL HEMATOLOGY, 32, 5, 450, 460, May 2004, [Peer-reviewed]
English, Scientific journal - Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma
T Endo, N Sato, Y Mogi, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, H Ikeda, T Koike
BONE MARROW TRANSPLANTATION, 33, 7, 703, 707, Apr. 2004, [Peer-reviewed]
English, Scientific journal - Effective high-dose chemotherapy combined with CD34(+)-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma
K Koizumi, K Fujimoto, Y Haseyama, T Endo, M Nishio, K Yokota, T Itoh, K Sawada, T Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 72, 2, 140, 144, Feb. 2004, [Peer-reviewed]
English, Scientific journal - Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient
T Endo, S Nakao, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, T Koike
ANNALS OF HEMATOLOGY, 83, 2, 114, 116, Feb. 2004, [Peer-reviewed]
English, Scientific journal - Myeloma cells, produce sialyl salivary-type amylase
M Shigemura, T Moriyama, T Endo, H Shibuya, H Suzuki, M Nishimura, H Chiba, K Matsuno
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 42, 6, 677, 680, 2004, [Peer-reviewed]
English - Granular lymphocyte proliferative disorder after autologous peripheral blood stem cell transplantation for multiple myeloma
K Kawakubo, T Endo, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Sawada, T Koike
EUROPEAN JOURNAL OF HAEMATOLOGY, 71, 2, 124, 127, Aug. 2003, [Peer-reviewed]
English, Scientific journal - Severe aplastic anemia associated with thymic carcinoma and partial recovery of hematopoiesis after thymectomy
K Koizumi, S Nakao, Y Haseyama, H Kato, M Ohi, T Motohara, T Endo, K Sawada, T Koike
ANNALS OF HEMATOLOGY, 82, 6, 367, 370, Jun. 2003, [Peer-reviewed]
English, Scientific journal - Tumor necrosis factor-alpha inhibits generation of glycophorin A(+) cells by CD34(+) cells
WG Xiao, K Koizumi, M Nishio, T Endo, M Osawa, K Fujimoto, Sato, I, T Sakai, T Koike, K Sawada
EXPERIMENTAL HEMATOLOGY, 30, 11, 1238, 1247, Nov. 2002, [Peer-reviewed]
English, Scientific journal - Stem cell factor protects c-kit(+) human primary erythroid cells from apoptosis
T Endo, A Odb, Satoh, I, Y Haseyama, M Nishio, K Koizumi, H Takashima, K Fujimoto, Y Amasaki, H Fujita, T Koike, K Sawada
EXPERIMENTAL HEMATOLOGY, 29, 7, 833, 841, Jul. 2001, [Peer-reviewed]
English, Scientific journal - A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
T Endo, T Sakai, K Fujimoto, S Yamamoto, H Takashima, Y Haseyama, M Nishio, K Koizumi, T Koike, K Sawada
BONE MARROW TRANSPLANTATION, 27, 4, 433, 436, Feb. 2001, [Peer-reviewed]
English, Scientific journal - Large scale purification of human blood CD34(+) cells from cryopreserved peripheral blood stem cells, using a nylon-fiber syringe system and immunomagnetic microspheres
K Koizumi, M Nishio, T Endo, H Takashima, Y Haseyama, K Fujimoto, S Yamamoto, N Sato, K Ikebuchi, H Ikeda, T Koike, K Sawada
BONE MARROW TRANSPLANTATION, 26, 7, 787, 793, Oct. 2000, [Peer-reviewed]
English, Scientific journal - Effective high-dose chemotherapy combined with CD34(+)-selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T cell lymphoma
M Nishio, K Koizumi, T Endo, H Takashima, Y Haseyama, K Fujimoto, S Yamamoto, H Kobayashi, T Koike, K Sawada
BONE MARROW TRANSPLANTATION, 25, 12, 1315, 1317, Jun. 2000, [Peer-reviewed]
English, Scientific journal - Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APBSCT) for cutaneous CD30-negative large T cell lymphoma
M Nishio, K Sawada, K Koizumi, T Tarumi, H Takano, T Endo, H Takashima, H Hashimoto, Y Haseyama, H Kobayashi, T Koike
BONE MARROW TRANSPLANTATION, 22, 12, 1211, 1214, Dec. 1998, [Peer-reviewed]
English, Scientific journal
Other Activities and Achievements
- VGCV中止による免疫回復にて改善を認めたCMV感染症合併のAIDS症例
横山翔大, 横山翔大, 遠藤知之, 遠藤知之, 宮島徹, 宮島徹, 須藤啓斗, 須藤啓斗, 高橋承吾, 高橋承吾, 長谷川祐太, 長谷川祐太, 荒隆英, 荒隆英, 松川敏大, 松川敏大, 後藤秀樹, 後藤秀樹, 橋野聡, 橋野聡, 豊嶋崇徳, 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022 - 当院における「いきなりエイズ」症例の患者特性の検討
荒隆英, 荒隆英, 遠藤知之, 遠藤知之, 宮島徹, 宮島徹, 須藤啓斗, 須藤啓斗, 高橋承吾, 高橋承吾, 横山翔大, 横山翔大, 長谷川祐太, 長谷川祐太, 松川敏大, 松川敏大, 後藤秀樹, 後藤秀樹, 橋野聡, 橋野聡, 豊嶋崇徳, 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022 - 薬害HIV感染症患者における冠動脈スクリーニング
遠藤知之, 遠藤知之, 後藤秀樹, 後藤秀樹, 松川敏大, 松川敏大, 荒隆英, 荒隆英, 長谷川祐太, 長谷川祐太, 横山翔大, 横山翔大, 高橋承吾, 高橋承吾, 須藤啓斗, 須藤啓斗, 宮島徹, 宮島徹, 橋野聡, 豊嶋崇徳, 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022 - HIV感染者に対する骨代謝異常の後方視的解析
松川敏大, 松川敏大, 遠藤知之, 遠藤知之, 宮島徹, 宮島徹, 須藤啓斗, 須藤啓斗, 高橋承吾, 高橋承吾, 横山翔大, 横山翔大, 長谷川祐太, 長谷川祐太, 荒隆英, 荒隆英, 後藤秀樹, 後藤秀樹, 橋野聡, 橋野聡, 橋野聡, 豊嶋崇徳, 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022 - Fluid retention after allogeneic hematopoietic stem cell transplantation has a poor prognosis
宮下直樹, 須藤啓斗, 日高大輔, 大東寛幸, 荒隆英, 白鳥聡一, 安本篤史, 後藤秀樹, 杉田純一, 小野澤真弘, 中川雅夫, 遠藤知之, 橋本大吾, 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - 2010~2020年度に実施したHIV-1薬剤耐性検査外部精度評価の報告
吉田繁, 松田昌和, 今橋真弓, 岡田清美, 齊藤浩一, 林田庸総, 佐藤かおり, 藤澤真一, 遠藤知之, 西澤雅子, 椎野禎一郎, 豊嶋崇徳, 杉浦亙, 吉村和久, 菊地正, 日本エイズ学会誌, 23, 4, 2021 - Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.
Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata, Bone marrow transplantation, 55, 7, 1399, 1409, 16 Mar. 2020, [International Magazine]
A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant., English - VWF含有第VIII因子製剤および第IX因子製剤を併用して関節手術を施行したVWD合併血友病B保因者
遠藤知之, 岡敏明, 小野寺智洋, 遠藤香織, 高橋承吾, 米田和樹, 荒隆英, 白鳥聡一, 後藤秀樹, 中川雅夫, 豊嶋崇徳, 日本血栓止血学会誌, 31, 2, 2020 - Prospective Evaluation of Alternative Donor from Unrelated Volunteer Donor and Cord Blood in Adult Acute Leukemia and Myelodysplastic Syndrome: No Difference between Unrelated Donor and Cord Blood
Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata, BLOOD, 134, Nov. 2019
English, Summary international conference - AMLにおけるWT1発現量と染色体・遺伝子異常の関連
日高 大輔, 小野澤 真弘, 橋口 淳一, 宮下 直洋, 笠原 耕平, 藤澤 真一, 早瀬 英子, 岡田 耕平, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 中川 雅夫, 加畑 馨, 橋本 大吾, 遠藤 知之, 山本 聡, 堤 豊, 長谷山 美仁, 永嶋 貴博, 盛 暁生, 太田 秀一, 酒井 基, 石原 敏道, 今井 陽俊, 宮城島 拓人, 柿木 康孝, 黒澤 光俊, 小林 一, 岩崎 博, 清水 力, 近藤 健, 豊嶋 崇徳, 臨床血液, 59, 7, 964, 964, Jul. 2018
(一社)日本血液学会-東京事務局, Japanese - ステロイド抵抗性急性移植片対宿主病に対するヒト間葉系幹細胞療法の後方視的解析
白鳥 聡一, 早瀬 英子, 岡田 耕平, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 中川 雅夫, 加畑 馨, 橋本 大吾, 遠藤 知之, 近藤 健, 豊嶋 崇徳, 日本輸血細胞治療学会誌, 64, 2, 452, 452, Apr. 2018
(一社)日本輸血・細胞治療学会, Japanese - Establishment of the Hokkaido HIV Dialysis Network and the Assessment of Its Efficacy
遠藤 知之, センテノ田村 恵子, 渡部 恵子, 後藤 秀樹, 宮下 直洋, 荒 隆英, 笠原 耕平, 橋野 聡, 豊嶋 崇徳, 日本エイズ学会誌 = The journal of AIDS research, 20, 3, 199, 205, 2018
日本エイズ学会, Japanese - Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation
Hiroyuki Nakamura, Shinsuke Yasuda, Atsushi Noguchi, Toshio Odani, Yuichiro Fujieda, Masaru Kato, Kenji Oku, Junichi Sugita, Toshiyuki Bohgaki, Tomoyuki Endo, Takanori Teshima, Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 69, Oct. 2017
English, Summary international conference - 脳生検により診断した進行性多巣性白質脳症の長期生存例
佐藤 翔紀, 白井 慎一, 高橋 育子, 矢部 一郎, 遠藤 知之, 豊嶋 崇徳, 山口 秀, 桑原 健, 畑中 佳奈子, 松野 吉宏, 今村 顕史, 三浦 義治, 中道 一生, 西條 政幸, 佐々木 秀直, NEUROINFECTION, 22, 2, 244, 244, Sep. 2017
日本神経感染症学会, Japanese - IgA型ALアミロイドーシスに線状IgA皮膚症を併発した1例
山口 泰之, 氏家 英之, 大東 寛幸, 岩田 浩明, 村松 憲, 清水 宏, 遠藤 知之, 豊嶋 崇徳, 日本皮膚科学会雑誌, 127, 9, 2111, 2111, Aug. 2017
(公社)日本皮膚科学会, Japanese - HIV/HCV重複感染肝硬変に対し脳死肝移植を施行した1例
杉山昂, 後藤了一, 川村典生, 腰塚靖之, 渡辺正明, 武冨紹信, 遠藤知之, 藤本勝也, 近藤健, 山下健一郎, 嶋村剛, 北海道外科雑誌, 62, 1, 96, 20 Jun. 2017
Japanese - IMATINIB VS. DASATINIB FOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH PH plus ACUTE LYMPHOBLASTIC LEUKEMIA
A. Shigematsu, S. Ota, H. Goto, K. Minauchi, J. Sugita, D. Hashimoto, M. Obara, T. Endo, M. Imamura, T. Teshima, N. Kobayashi, HAEMATOLOGICA, 102, 354, 354, Jun. 2017
English, Summary international conference - 当院においてドナーリンパ球輸注を施行した34症例の検討
石尾 崇, 立野 貴大, 笠原 耕平, 小杉 瑞葉, 白鳥 聡一, 岡田 耕平, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳, 日本輸血細胞治療学会誌, 63, 2, 148, 149, Apr. 2017
(一社)日本輸血・細胞治療学会, Japanese - HIV/HCV重複感染者に対するソホスブビルを投与(多施設共同研究)
四柳 宏, 遠藤 知之, 塚田 訓久, 潟永 博之, 三田 英治, 菊地 正, 鯉渕 智彦, 木村 哲, 感染症学雑誌, 91, 臨増, 278, 278, Mar. 2017
(一社)日本感染症学会, Japanese - 半夏瀉心湯による移植関連口腔粘膜炎の予防効果に関する検討
岡田耕平, 重松明男, 中澤誠多朗, 松下貴惠, 山崎裕, 杉田純一, 笠師久美子, 池田陽子, 早瀬英子, 白鳥聡一, 後藤秀樹, 小野澤真弘, 中川雅夫, 加畑馨, 橋本大吾, 遠藤知之, 近藤健, 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - Intrabone Transplantation of a Single Cord Blood Unit Using Non-Irradiated Reduced-Intensity Conditioning
Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Tadashi Matsushita, Yoshihisa Kodera, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida, BLOOD, 128, 22, Dec. 2016
English, Summary international conference - 胆嚢炎症状を契機に発症したTAFRO症候群
関根 隆博, 後藤 秀樹, 日高 大輔, 早瀬 英子, 小杉 瑞葉, 岡田 耕平, 白鳥 総一郎, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳, 臨床血液, 57, 12, 2608, 2608, Dec. 2016
(一社)日本血液学会-東京事務局, Japanese - HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
遠藤知之, 遠藤知之, 宮下直洋, 宮下直洋, 笠原耕平, 笠原耕平, 小杉瑞葉, 岡田耕平, 白鳥聡一, 後藤秀樹, 杉田純一, 小野澤真弘, 橋本大吾, 加畑馨, 藤本勝也, 藤本勝也, 近藤健, 橋野聡, 橋野聡, 豊嶋崇徳, 豊嶋崇徳, 日本エイズ学会誌, 18, 4, 439, 439, 20 Nov. 2016
(一社)日本エイズ学会, Japanese - 肺胞蛋白症を合併し致死的な経過を辿った骨髄異形成症候群の1例
大東 寛幸, 松川 敏大, 金谷 穣, 後藤 秀樹, 橋本 大吾, 加畑 馨, 遠藤 知之, 田中 伸哉, 豊嶋 崇徳, 臨床血液, 57, 11, 2398, 2398, Nov. 2016
(一社)日本血液学会-東京事務局, Japanese - HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
遠藤 知之, 宮下 直洋, 笠原 耕平, 小杉 瑞葉, 岡田 耕平, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 近藤 健, 橋野 聡, 豊嶋 崇徳, 日本エイズ学会誌, 18, 4, 439, 439, Nov. 2016
日本エイズ学会, Japanese - 多職種で連携して診療にあたったHIV合併妊娠管理についての検討
金川 明功, 小島 崇史, 山田 崇弘, 長 和俊, 遠藤 知之, 西村 あや子, 石川 聡司, 森川 守, 山田 俊, 近藤 健, 水上 尚典, 北日本産科婦人科学会総会・学術講演会プログラム・抄録集, 64回, 145, 145, Sep. 2016
東北連合産科婦人科学会・北日本産科婦人科学会, Japanese - 当院における同種末梢血幹細胞採取の検討
杉田 純一, 大東 寛幸, 橋口 淳一, 松川 敏大, 金谷 穣, 小杉 瑞葉, 松岡 里湖, 後藤 秀樹, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳, 日本輸血細胞治療学会誌, 62, 3, 490, 490, Jun. 2016
(一社)日本輸血・細胞治療学会, Japanese - 【エイズの臨床 アップデート】 医療現場における曝露後予防
遠藤 知之, アレルギー・免疫, 23, 5, 702, 707, Apr. 2016
(株)医薬ジャーナル社, Japanese - 【すべての内科医のためのHIV感染症-長期管理の時代に】 HIV感染症にまつわるFAQ HIVに求められる感染対策
遠藤 知之, 内科, 116, 5, 815, 819, Nov. 2015
(株)南江堂, Japanese - Cardio-ankle vascular index(CAVI)を用いたHIV感染者の動脈硬化の評価とリスク因子の検討
遠藤 知之, 宮下 直洋, 笠原 耕平, 渡部 恵子, 武内 阿味, 松川 敏大, 金谷 穣, 小杉 瑞葉, 松岡 里湖, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 近藤 健, 橋野 聡, 豊嶋 崇徳, 日本エイズ学会誌, 17, 4, 392, 392, Nov. 2015
日本エイズ学会, Japanese - 初回ART導入におけるRaltegravirとDolutegravirの血液毒性への関与
後藤 秀樹, 遠藤 知之, 藤本 勝也, 近藤 健, 加畑 馨, 橋本 大吾, 小野澤 真弘, 杉田 純一, 松川 敏大, 笠原 耕平, 宮下 直洋, 橋野 聡, 佐藤 典宏, 豊嶋 崇徳, 日本エイズ学会誌, 17, 4, 510, 510, Nov. 2015
日本エイズ学会, Japanese - 【危惧する感染症-院内感染防止対策-】 HIV感染症
遠藤 知之, Surgery Frontier, 22, 3, 209, 215, Sep. 2015
(株)メディカルレビュー社, Japanese - 当院におけるHIV感染者のビタミンDの検討
遠藤 知之, 藤本 勝也, 南 昭子, 吉田 美穂, 竹村 龍, 渡部 恵子, 坂本 玲子, 武内 阿味, 近藤 健, 橋野 聡, 清水 力, 豊嶋 崇徳, 日本エイズ学会誌, 17, 1, 30, 35, Feb. 2015
HIV感染者におけるビタミンDの充足率を把握し、骨密度低下と因果関係を評価した。方法は著者らの施設へ通院中のHIV患者118例(男性115例、女性3例、年齢24〜73歳、平均年齢43歳)を対象に、血清25水酸化ビタミンD[25(OH)D]を測定、そのうち100例でDXA法による骨塩量測定検査を行った。その結果、1)血清25(OH)Dの平均値は18.5±11.0ng/mlであり、ビタミンD不足(20〜29ng/dl)は24例(20.3%)、ビタミンD欠乏(20ng/dl以下)が79例(67.0%)にみられた。更にビタミンD高度欠乏(10ng/ml以下)は26例(22.0%)にみられ、ビタミンD正常(30ng/ml以上)は15例(12.7%)に過ぎなかった。2)100例におけるDXA法による骨塩定量測定では骨減少症は27例(27.0%)、骨粗鬆症は8例(8%)であった。3)このことからビタミンDの充足度と骨密度には有意な相関は認められなかったが、抗HIV療法を受けている症例では未治療の症例と比較して有意に骨密度が低下していた。4)多くのHIV患者でビタミンDが不足・欠乏していたが、骨密度低下の要因としてはビタミンD欠乏より抗HIV薬の影響が大きいと考えられた。以上より、HIV患者にビスホスフォネートを投与する際にはビタミンDの評価を行い、ビタミンDが低下・欠乏している症例に対するビタミンDの補充も必要と考えられた。, 日本エイズ学会, Japanese - 臍帯血移植後にNeurolymphomatosisとして再発したDouble hit lymphoma
宮下 直洋, 岡田 耕平, 佐賀 智之, 小笠原 励起, 井端 淳, 高畑 むつみ, 重松 明男, 遠藤 知之, 豊嶋 崇徳, 臨床血液, 55, 7, 845, 845, Jul. 2014
(一社)日本血液学会-東京事務局, Japanese - 当科におけるHCV/HIV重複感染症の現状と抗HCV療法
荘 拓也, 中馬 誠, 常松 聖司, 佐藤 史幸, 佃 曜子, 寺下 勝巳, 中井 正人, 堀本 啓大, 須田 剛生, 夏井坂 光輝, 藤本 勝也, 遠藤 知之, 豊嶋 崇徳, 坂本 直哉, 肝臓, 55, Suppl.1, A213, A213, Apr. 2014
(一社)日本肝臓学会, Japanese - 北海道内のHIV感染症患者におけるHBV・HCV重複感染の現状
藤本勝也, 遠藤知之, 吉田美穂, 竹村龍, 近藤健, 橋野聡, 須田剛生, 中馬誠, 後藤了一, センテノ田村恵子, 渡部恵子, 大野稔子, 石田禎夫, 大竹孝明, 宮城島拓人, 小林一, 堤豊, 三宅高義, 北川浩彦, 佐藤典宏, 豊嶋崇徳, 日本エイズ学会誌, 16, 1, 18, 27, Feb. 2014 - 臨床 抗HIV療法 テノホビル/エムトリシタビン・ロピナビル/リトナビル内服例を現行レジメンとラルテグラビル・ダルナビル/リトナビルに無作為割付する多施設共同臨床試験
西島 健, 潟永 博之, 遠藤 知之, 堀場 昌英, 古賀 道子, 内藤 俊夫, 井戸田 一朗, 鄭 真徳, 藤井 輝久, 高田 清式, 山本 政弘, 宮川 寿一, 田邊 嘉也, 満屋 裕明, 岡 慎一, 日本エイズ学会誌, 15, 4, 375, 375, Nov. 2013
(一社)日本エイズ学会, Japanese - CD4-/CD8-進行性表皮向性細胞傷害性T細胞リンパ腫の1例
宮内 俊成, 西村 真智子, 柴 景子, 齋藤 奈央, 阿部 理一郎, 清水 宏, 岡田 耕平, 重松 明男, 遠藤 知之, 豊島 崇徳, 河井 一浩, 日本皮膚科学会雑誌, 123, 8, 1548, 1548, Jul. 2013
(公社)日本皮膚科学会, Japanese - HIV感染者における梅毒血清反応と抗カルジオリピン抗体に関する検
遠藤知之, 藤本勝也, 吉田美穂, 竹村龍, 杉田純一, 重松明男, 近藤健, 橋野聡, 田中淳司, 日本エイズ学会誌, 15, 2, 113, 118, May 2013 - 異性間同種造血幹細胞移植後のキメリズム解析における再発とドナー由来白血病の判別
松川 敏大, 重松 明男, 早坂 光司, 藤澤 真一, 浅沼 真介, 安本 篤史, 後藤 秀樹, 高畑 むつみ, 遠藤 知之, 田中 淳司, 橋野 聡, 今村 雅寛, 豊嶋 崇徳, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 88, 2, 93, 93, 01 Apr. 2013
Japanese - 当院でのAML,MDS同種造血幹細胞移植症例における移植前後のWT‐1推移
井端淳, 遠藤知之, 重松明男, 高畑むつみ, 安本篤史, 岡田耕平, 大庭幸治, 佐久嶋研, 西村千佳子, 佐藤典宏, 橋野聡, 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 228, 08 Feb. 2013
Japanese - Chimerism analyses by sex-chromosome analysis confused relapse with donor cell leukemia after sex-mismatched allo-SCT
T. Matsukawa, A. Shigematsu, K. Hayasaka, S. Fujisawa, S. Asanuma, A. Yasumoto, H. Goto, M. Takahata, T. Endo, J. Tanaka, S. Hashino, C. Shimizu, M. Imamura, Bone Marrow Transplantation, 47, 12, 1583, 1584, Dec. 2012
English, Report scientific journal - Webサイト「北海道HIV/AIDS情報」の利用についての検証―利用状況とwebサイト開設が与えた影響から―
センテノ田村恵子, センテノ田村恵子, 坂本玲子, 坂本玲子, 江端あい, 江端あい, 加藤朋子, 富田健一, 渡部恵子, 遠藤知之, 佐藤典宏, 日本エイズ学会誌, 14, 4, 445, 445, 20 Nov. 2012
(一社)日本エイズ学会, Japanese - 北海道内のHIV感染症患者におけるHBV・HCV重複感染の現状〜拠点病院・診療施設アンケート調査結果〜
藤本勝也, 吉田美穂, 吉田美穂, 竹村龍, 竹村龍, 遠藤知之, 近藤健, 田中淳司, 橋野聡, 中西満, 中馬誠, 後藤了一, センテノ(田村, 恵子, センテノ(田村, 恵子, 渡部恵子, 大野稔子, 石田禎夫, 大竹孝明, 宮城島拓人, 小林一, 堤豊, 三宅高義, 北川浩彦, 佐藤典弘, 日本エイズ学会誌, 14, 4, 406, 20 Nov. 2012
Japanese - 当院におけるHIV感染者の骨代謝異常の検討
遠藤知之, 遠藤知之, 藤本勝也, 藤本勝也, 吉田美穂, 吉田美穂, 吉田美穂, 竹村龍, 竹村龍, 竹村龍, 杉田純一, 杉田純一, 重松明男, 重松明男, 近藤健, 近藤健, 田中淳司, 田中淳司, 橋野聡, 佐藤典宏, 佐藤典宏, 日本エイズ学会誌, 14, 4, 391, 391, 20 Nov. 2012
(一社)日本エイズ学会, Japanese - Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD
杉田 純一, 松下 貴恵, 柏崎 晴彦, 高橋 正二郎, 白鳥 聡一, 井端 淳, 重松 明男, 藤本 勝也, 遠藤 知之, 近藤 健, 橋野 聡, 田中 淳司, 豊嶋 崇徳, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 6, 272, 272, 01 Nov. 2012
Japanese - Lymphopenia and an Elevated Monocyte Count At Diagnosis Do Not Predict a Poor Outcome After Autologous Transplants for Diffuse Large B-Cell Lymphoma in the First Remission
Mitsufumi Nishio, Satoshi Yamamoto, Tomoyuki Endo, Katsuya Fujimoto, Toshiya Sakai, Takeshi Kondo, Akio Shigematsu, Junichi Sugita, Satoshi Hashino, Junji Tanaka, Masahiro Imamura, Takanori Teshima, BLOOD, 120, 21, Nov. 2012
English, Summary international conference - 初回治療でアタザナビル/リトナビルを固定しエプジコムとツルバダを無作為割付するオープンラベル多施設臨床試験 ET study 96週結果
西島 健, 高野 操, 石坂 美千代, 潟永 博之, 菊池 嘉, 遠藤 知之, 堀場 昌英, 金田 暁, 鯉渕 智彦, 内藤 俊夫, 吉田 正樹, 立川 夏夫, 横幕 能行, 藤井 輝久, 高田 清式, 山本 政弘, 松下 修三, 健山 正男, 田邊 嘉也, 満屋 裕明, 岡 慎一, 日本エイズ学会誌, 14, 4, 306, 306, Nov. 2012
(一社)日本エイズ学会, Japanese - 【血友病診療の最前線〜症例から学ぶ〜】Case Conference 血友病診療の実際 血友病A 頭蓋内に偽腫瘍が発生した血友病Aの一例
安本 篤史, 遠藤 知之, 血液フロンティア, 22, 9, 1329, 1332, Aug. 2012
(株)医薬ジャーナル社, Japanese - 臍帯血細胞移植後にサイトメガロウイルス脳室脳炎を発症した菌状息肉症の一剖検例
高橋健太, 松川敏大, 後藤秀樹, 遠藤知之, 橋野聡, 木村太一, 谷野美智枝, 西原広史, 田中伸哉, 田中伸哉, 日本病理学会会誌, 101, 1, 300, 26 Mar. 2012
Japanese, Others - 急性混合性白血病に対する同種臍帯血移植後にHHV‐6肺炎を発症した一例
石尾崇, 重松明男, 遠藤知之, 田中淳司, 坂井俊哉, 橋野聡, 山本聡, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 200, 01 Feb. 2012
Japanese - 臍帯血移植後にサイトメガロウィルス(CMV)脳症を発症した菌状息肉症
松川敏大, 後藤秀樹, 遠藤知之, 重松明男, 高畑むつみ, 安本篤史, 浅沼真介, 橋野聡, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 244, 01 Feb. 2012
Japanese - 中等量VP‐16/CY/TBI前処置を用いた同種造血幹細胞移植における移植関連死亡
重松明男, 重松明男, 杉田純一, 高畑むつみ, 遠藤知之, 近藤健, 田中淳司, 橋野聡, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 226, 01 Feb. 2012
Japanese - G‐CSF投与による末梢血(PB)CD34陽性細胞(CD34+)上の接着因子,CD90,CD117の変化とPBSC採取収率
政氏伸夫, 田中淳司, 笠井正晴, 小笠原正浩, 小林直樹, 木山善雄, 杉田純一, 重松明男, 藤本勝也, 遠藤知之, 近藤健, 小林正伸, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 241, 01 Feb. 2012
Japanese - HBワクチンによる造血細胞移植後のHBV再燃予防の試み〜長期予後の検討〜
高畑むつみ, 小野澤真弘, 橋野聡, 重松明男, 遠藤知之, 杉田純一, 藤本勝也, 近藤健, 田中淳司, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 295, 01 Feb. 2012
Japanese - ValGCV experience at Hokkaido University Hospital
TAKAHASHI SHOJIRO, WAKASA KENTARO, IBATA MAKOTO, SHIGEMATSU AKIO, HUJIMOTO KATUYA, ENDO TOMOYUKI, NISHIO MITUHUMI, KONDOU TAKESHI, TANAKA JUNJI, HASHINO SATOSHI, ASAKA MASAHIRO, IMAMURA MASAHIRO, 無菌生物 = Japanese journal of germfree life and gnotobiology, 41, 2, 106, 107, 01 Dec. 2011
Japanese - HIV感染者における梅毒血清反応と抗カルジオリピン抗体に関する検討
遠藤知之, 藤本勝也, 後藤秀樹, 白鳥聡一, 杉田純一, 重松明男, 西尾充史, 近藤健, 田中淳司, 橋野聡, 今村雅寛, 佐藤典宏, 日本エイズ学会誌, 13, 4, 363, 363, 20 Nov. 2011
(一社)日本エイズ学会, Japanese - 多施設共同疫学調査におけるHAARTの有効率2010
菊池 嘉, 遠藤 知之, 宮城島 拓人, 伊藤 俊広, 中村 仁美, 田邊 嘉也, 上田 幹夫, 横幕 能行, 渡邊 大, 藤井 輝久, 南 留美, 健山 正男, 日本エイズ学会誌, 13, 4, 463, 463, Nov. 2011
(一社)日本エイズ学会, Japanese - Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma, Nasal Type: Analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group
Ritsuro Suzuki, Shinichi Kako, Rie Hyo, Koji Izutsu, Toshiro Ito, Katsuji Shinagawa, Tomoyuki Endo, Hisashi Sakamaki, Junji Suzumiya, BLOOD, 118, 21, 235, 235, Nov. 2011
English, Summary international conference - Both DOCK180 and DOCK2 Participate in the CXCL12 and CCL19 Dependent Chemotaxis of Human Dendritic Cells Derived From Monocytes Through the Activation of Rac
Hideki Goto, Mitsufumi Nishio, Katsuya Fujimoto, Tomoyuki Endo, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hiroshi Nishihara, Takao Koike, Masahiro Imamura, BLOOD, 118, 21, 242, 243, Nov. 2011
English, Summary international conference - HIV感染症の初回治療でアタザナビル/リトナビルを固定しエプジコムとツルバダを無作為割付するオープンラベル多施設臨床試験 ET study
西島 健, 高野 操, 石坂 美千代, 潟永 博之, 菊池 嘉, 遠藤 知之, 堀場 昌英, 金田 暁, 藤井 毅, 内藤 俊夫, 吉田 正樹, 立川 夏夫, 横幕 能行, 藤井 輝久, 高田 清式, 山本 政弘, 松下 修三, 健山 正男, 田邊 嘉也, 満屋 裕明, 岡 慎一, 日本エイズ学会誌, 13, 4, 417, 417, Nov. 2011
(一社)日本エイズ学会, Japanese - Management of oral mucositis after allogeneic stem cell transplantation
SUGITA JUNICHI, MATSUSHITA TAKAE, KASHIWAZAKI HARUHIKO, KOSUGI MIZUHA, TAKAHASHI SHOJIRO, WAKASA KENTARO, SHIRATORI SOUICHI, IBATA MAKOTO, SHONO YUSUKE, SHIGEMATSU AKIO, OBARA MASATO, FUJIMOTO KATSUYA, ENDO TOMOYUKI, NISHIO MITSUFUMI, KONDO TAKESHI, HASHINO SATOSHI, TANAKA JUNJI, ASAKA MASAHIRO, IMAMURA MASAHIRO, Journal of germfree life and gnotobiology, 41, 1, 48, 53, 01 Sep. 2011
日本無菌生物ノートバイオロジー学会, Japanese - HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T-CELL LYMPHOMA, NASAL-TYPE: THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT) LYMPHOMA WORKING PARTY
R. Suzuki, S. Kako, R. Hyo, K. Izutsu, T. Ito, K. Shinagawa, T. Endo, H. Sakamaki, J. Suzumiya, ANNALS OF ONCOLOGY, 22, 95, 95, Jun. 2011
English, Summary international conference - Successful combination therapy by meropenem and colistin for multi-drug-resistant Pseudomonas aeruginosa infection after allogeneic bone marrow transplantation
KANDA Masatoshi, SHIGEMATSU Akio, OKADA Kohei, KASAHARA Ikumi, IWASAKI Junko, YAMAGUCHI Keisuke, ONOZAWA Masahiro, ENDO Tomoyuki, AKIZAWA Koji, ISHIGURO Nobuhiro, HASHINO Satoshi, IMAMURA Masahiro, The Japanese journal of clinical hematology, 52, 3, 118, 123, 30 Mar. 2011
「臨床血液」編集部, Japanese - HLA適合度とGVHD予防法が移植成績に及ぼす影響の後方視的検討
笠原郁美, 小林直樹, 重松明男, 小原雅人, 西尾充史, 遠藤知之, 藤本勝也, 武田紫, 山口圭介, 杉田純一, 後藤秀樹, 近藤健, 太田秀一, 今井陽俊, 橋野聡, 田中淳司, 小池隆夫, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 242, 2011
Japanese - AIDS関連リンパ腫の治療後に全身リンパ節腫脹をきたしたEBV related HIV‐lymphadenitisの一例
岩崎純子, 岩崎純子, 岡田耕平, 岡田耕平, 笠原郁美, 笠原郁美, 山口圭介, 山口圭介, 重松明男, 重松明男, 小野澤真弘, 小野澤真弘, 遠藤知之, 遠藤知之, 柿木康孝, 橋野聡, 橋野聡, 小池隆夫, 今村雅寛, 今村雅寛, 浅香正博, 日本エイズ学会誌, 12, 4, 467, 20 Nov. 2010
Japanese - HAART開始後のHIV‐RNA早期抑制の臨床的意義に関する検討
遠藤知之, 後藤秀樹, 白鳥聡一, 渡部恵子, 杉田純一, 重松明男, 小原雅人, 藤本勝也, 西尾充史, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 佐藤典宏, 小池隆夫, 日本エイズ学会誌, 12, 4, 374, 374, 20 Nov. 2010
(一社)日本エイズ学会, Japanese - 急性及び慢性消化管GVHDに対するbeclomethasone dipropioneteの使用経験
高橋正二郎, 高橋正二郎, 若狭健太郎, 若狭健太郎, 井端淳, 井端淳, 重松明男, 重松明男, 藤本勝也, 藤本勝也, 遠藤知之, 遠藤知之, 西尾充史, 西尾充史, 近藤健, 近藤健, 笠師久美子, 深井敏隆, 山田武広, 田中淳司, 田中淳司, 橋野聡, 橋野聡, 井関健, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛, 臨床血液, 51, 9, 999, 30 Sep. 2010
Japanese - 急性及び慢性消化管GVHDに対するbeclomethasone dipropioneteの使用経験
岡田耕平, 岡田耕平, 岩崎純子, 岩崎純子, 笠原郁美, 笠原郁美, 山口圭介, 山口圭介, 重松明男, 重松明男, 小野澤真弘, 小野澤真弘, 遠藤知之, 遠藤知之, 西尾充史, 西尾充史, 近藤健, 近藤健, 久保田康生, 笠師久美子, 深井敏隆, 田中淳司, 田中淳司, 橋野聡, 橋野聡, 井関健, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 248, 2010
Japanese - 同種幹細胞移植後に急性転化で再発したイマチニブ不応の慢性骨髄性白血病に,再移植前の疾患コントロールとしてダサチニブが有効であった1例
後藤秀樹, 西尾充史, 遠藤知之, 山本聡, 小原雅人, 山口圭介, 武田紫, 笠原郁美, 佐藤典宏, 小池隆夫, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 243, 2010
Japanese - TaqMan PCR定性法を用いたEfavirenzとAtazanavirの治療効果の比較
遠藤知之, 西尾充史, 山口圭介, 藤澤真一, 小野澤真弘, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 佐藤典宏, 小池隆夫, 日本エイズ学会誌, 11, 4, 507, 507, 20 Nov. 2009
(一社)日本エイズ学会, Japanese - CD34陽性急性白血病と正常CD34陽性細胞におけるDOCK180発現
山口圭介, 西尾充史, 坂井俊哉, 遠藤知之, 武田紫, 後藤秀樹, 笠原郁美, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 西原広史, 小池隆夫, 臨床血液, 50, 9, 944, 30 Sep. 2009
Japanese, Others - 当科におけるreduced intensity conditioning(RIC)regimenの違いによる治療成績の比較検討
山本聡, 西尾充史, 遠藤知之, 武田紫, 山口圭介, 後藤秀樹, 笠原郁美, 佐藤典宏, 小池隆夫, 臨床血液, 50, 9, 1105, 1105, 30 Sep. 2009
(一社)日本血液学会-東京事務局, Japanese - 北海道大学病院におけるCBF‐AML,AML(M3)のRISTレジメンによる移植成績
在田幸太郎, 近藤健, 安本篤志, 杉田純一, 重松明男, 小野澤真弘, 遠藤知之, 西尾充史, 佐藤典宏, 橋野聡, 田中淳司, 今村雅寛, 臨床血液, 50, 9, 1094, 1094, 30 Sep. 2009
(一社)日本血液学会-東京事務局, Japanese - 同種造血幹細胞移植における真菌感染予防のためのFluconazoleとItaconazoleの比較
笠原郁美, 西尾充史, 遠藤知之, 武田紫, 山口圭介, 後藤秀樹, 佐藤典宏, 小池隆夫, 臨床血液, 50, 9, 1086, 30 Sep. 2009
Japanese - TaqMan PCR定性法によるHIV‐RNA測定の臨床的意義に関する検討
遠藤知之, 藤澤真一, 西尾充史, 山本聡, 小原雅人, 橋野聡, 今村雅寛, 佐藤典宏, 小池隆夫, 日本エイズ学会誌, 10, 4, 456, 456, 20 Nov. 2008
(一社)日本エイズ学会, Japanese - 血友病合併のHIV/HCV重複感染者に対するC型肝炎治療
髭修平, 中西満, 中馬誠, 堀本啓大, 小原俊央, 小野澤真弘, 加畑馨, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 遠藤知之, 佐藤典宏, 小池隆夫, 渡部恵子, 大野稔子, 浅香正博, 日本エイズ学会誌, 10, 4, 411, 411, 20 Nov. 2008
(一社)日本エイズ学会, Japanese - DOCK180, a New Surrogate Marker to Distinguish CD34 Positive Acute Leukemia Cells from CD34 Positive Normal Hematopoietic Stem/Progenitor Cells
Mitsufumi Nishio, Kohki Kumano, Katsuya Fujimoto, Tomoyuki Endo, Satoshi Yamamoto, Akio Shigematsu, Takeshi Kondo, Junji Tanaka, Satoshi Hashino, Masahiro Imamura, Hiroshi Nishihara, Norihiro Sato, Takao Koike, BLOOD, 112, 11, 525, 525, Nov. 2008
English, Summary international conference - FCGR3A-158V/F Polymorphism May Correlate with the Levels of Immunoglobulin in Patients with Non-Hodgkin's Lymphoma after Rituximab Treatment as An Adjuvant to Autologous Stem Cell Transplantation
Mitsufumi Nisino, Tomoyuki Endo, Katsuya Fujimoto, Satoshi Yamamoto, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike, BLOOD, 112, 11, 1115, 1115, Nov. 2008
English, Summary international conference - 骨髄非破壊的前処置を用いた同種骨髄移植後のサイトメガロウイルス感染症‐骨髄破壊的前処置との比較‐
重松明男, 重松明男, 杉田純一, 杉田純一, 山本聡, 山本聡, 岡田耕平, 岡田耕平, 小野澤真弘, 小野澤真弘, 加畑馨, 加畑馨, 遠藤知之, 遠藤知之, 安本篤史, 安本篤史, 高畑むつみ, 高畑むつみ, 西尾充史, 西尾充史, 近藤健, 近藤健, 橋野聡, 橋野聡, 田中淳司, 田中淳司, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛, 臨床血液, 49, 9, 874, 30 Sep. 2008
Japanese - ヒト正常血液細胞分化に伴うDOCK180の発現量変化
熊野弘毅, 西尾充史, 藤本勝也, 西原広史, 遠藤知之, 山本聡, 坂井俊哉, 小原雅人, 田中伸哉, 佐藤典宏, 小池隆夫, 臨床血液, 49, 9, 1194, 1194, 30 Sep. 2008
(一社)日本血液学会-東京事務局, Japanese - LevofloxacinとPolymyxin Bを消化管殺菌として好中球減少期に投与された血液悪性疾患119例での感染症合併
後藤秀樹, 西尾充史, 遠藤知之, 山本聡, 小原雅人, 山口圭介, 武田紫, 笠原郁美, 佐藤典宏, 小池隆夫, 臨床血液, 49, 9, 870, 870, 30 Sep. 2008
(一社)日本血液学会-東京事務局, Japanese - MCVC療法を前処置とした再発および初回治療抵抗性悪性リンパ腫36例に対する自家末梢血幹細胞移植
西尾充史, 遠藤知之, 山本聡, 重松明男, 小原雅人, 山口圭介, 武田紫, 後藤秀樹, 笠原郁美, 佐藤典宏, 橋野聡, 近藤健, 加畑馨, 小野澤真弘, 田中淳司, 今村雅寛, 浅香正博, 小池隆夫, 臨床血液, 49, 9, 1172, 1172, 30 Sep. 2008
(一社)日本血液学会-東京事務局, Japanese - Infectious complications following allogeneic bone marrow transplantation using reduced-intensity conditioning regimen
SHIGEMATSU AKIO, SUGITA JUNICHI, YAMAMOTO SATOSHI, ONOZAWA MASAHIRO, ENDO TOMOYUKI, KAHATA KAORU, SHIRATORI SOICHI, WAKASA KENTARO, TAKAHATA MUTSUMI, KONDO TAKESHI, TANAKA JUNJI, NISHIO MITSUFUMI, HASHINO SATOSHI, KOIKE TAKAO, ASAKA MASAHIRO, IMAMURA MASAHIRO, Journal of germfree life and gnotobiology, 38, 1, 27, 32, 01 Sep. 2008
日本無菌生物ノートバイオロジー学会, Japanese - Reversible cardiomyopathy due to secondary hemochromatosis with multitransfusions for severe aplastic anemia after successful non-myeloablative stem cell transplantation
M. Nishio, T. Endo, S. Nakao, N. Sato, T. Koike, INTERNATIONAL JOURNAL OF CARDIOLOGY, 127, 3, 400, 401, Jul. 2008
English, Report scientific journal - 北海道大学病院で施行された,悪性リンパ腫に対する骨髄非破壊的同種造血幹細胞移植
安本篤志, 重松明男, 近藤健, 山本聡, 杉田純一, 小野澤真宏, 遠藤知之, 高畑むつみ, 田中淳司, 橋野聡, 西尾充史, 小池隆夫, 浅香正博, 今村雅寛, 日本リンパ網内系学会会誌, 48, 107, 09 May 2008
Japanese - HAART施行中に限局性Mycobacterium avium関節炎/骨髄炎をきたしたHIV感染者の一例
遠藤知之, 藤本勝也, 山本聡, 西尾充史, 渡辺直也, 眞島任史, 佐藤典宏, 小池隆夫, 日本エイズ学会誌, 9, 4, 517, 517, 20 Nov. 2007
(一社)日本エイズ学会, Japanese - Chronic lymphocytic leukemia cells produce a soluble factor(s) that can induce CD14+blood mononuclear cells to assume properties of nurselike cells in vitro.
Davorka Messmer, Hsu-Hsiang Chang, Tomoyuki Endo, Thomas J. Kipps, BLOOD, 110, 11, 345A, 345A, Nov. 2007
English, Summary international conference - 当科における多発性骨髄腫に対する自家末梢血幹細胞移植の治療成績
山本聡, 西尾充史, 遠藤知之, 藤本勝也, 坂井俊哉, 小原雅人, 熊野弘毅, 武田紫, 山口圭介, 後藤秀樹, 佐藤典宏, 小池隆夫, 臨床血液, 48, 9, 1132, 1132, 30 Sep. 2007
(一社)日本血液学会-東京事務局, Japanese - 非ホジキンリンパ腫に対するリツキシマブ併用自家移植後の免疫グロブリン値とFCGR3Aの遺伝子多型
西尾 充史, 遠藤 知之, 藤本 勝也, 山本 聡, 坂井 俊哉, 熊野 弘毅, 小原 雅人, 山口 圭介, 武田 紫, 後藤 秀樹, 佐藤 典宏, 堀田 哲也, 中川 久子, 小池 隆夫, 臨床血液, 48, 9, 980, 980, Sep. 2007
(一社)日本血液学会-東京事務局, Japanese - Multiple myeloma associated with sialyl salivary-type amylase (vol 376, pg 121, 2007)
Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura, CLINICA CHIMICA ACTA, 380, 1-2, 254, 254, May 2007
English, Others - Ethacrynic acid can inhibit Wnt/beta-Catenin signaling and induce apoptosis in chronic lymphocytic leukemia cells.
Jerry X. Liu, Tomoyuki Endo, Thomas J. Kipps, Carson A. Dennis, Lu Desheng, BLOOD, 108, 11, 595A, 595A, Nov. 2006
English, Summary international conference - Chronic lymphocytic leukemia cells can induce monocytes to express high levels of BAFF and assume properties of nurselike cells in vitro.
Davorka Messmer, Tomoyuki Endo, Bradley T. Messmer, Thomas J. Kipps, BLOOD, 108, 11, 177A, 177A, Nov. 2006
English, Summary international conference - Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia (vol 75, pg 527, 2005)
M Nishio, T Endo, K Fujimoto, N Sato, T Sakai, M Obara, K Kumano, K Minauchi, T Koike, EUROPEAN JOURNAL OF HAEMATOLOGY, 76, 1, 91, 91, Jan. 2006
English, Others - AIDS患者に生じた Toxic epidermal necrolysis (TEN) に対し, 血漿交換療法が奏効した1例
乃村 俊史, 阿部 理一郎, 藤本 勝也, 遠藤 知之, 小池 隆夫, 清水 宏, 日本皮膚科学会雑誌 = THE JAPANESE JOURNAL OF DERMATOLOGY, 115, 13, 2236, 2238, Dec. 2005
日本皮膚科学会, Japanese - BAFF and APRIL protect CLL B cells from apoptosis through activation of NF-kappa B canonical pathway.
T Endo, M Nishio, T Fukuda, HB Cottam, SL Kalled, TJ Kipps, BLOOD, 106, 11, 56A, 56A, Nov. 2005
English, Summary international conference - 急性増悪時に著明な高アミラーゼ血症をきたしたシアリル化唾液腺型アミラーゼ産生多発性骨髄腫の一例
小原雅人, 重村雅彦, 遠藤知之, 山口圭介, 武田紫, 山倉昌之, 皆内康一郎, 熊野弘毅, 坂井俊哉, 藤本勝也, 山本聡, 西尾充史, 佐藤典宏, 小池隆夫, 臨床血液, 46, 8, 868, 30 Aug. 2005
Japanese - Chronic lymphocytic leukemia cells may become less dependent on nurse-like cells during later stages of disease.
T Endo, M Nishio, L Rassenti, AP Kater, TJ Kipps, BLOOD, 104, 11, 284B, 284B, Nov. 2004
English, Summary international conference - 当科における進行期follicular lymphomaに対する自家末梢血幹細胞移植併用超大量化学療法の治療成績
藤本 勝也, 山倉 昌之, 皆内 康一郎, 小原 雅人, 熊野 弘毅, 坂井 俊哉, 遠藤 知之, 西尾 充史, 佐藤 典宏, 高島 英典, 能登谷 京, 向井 正也, 小池 隆夫, 日本血液学会・日本臨床血液学会総会プログラム・抄録集, 66回・46回, 798, 798, Sep. 2004
日本臨床血液学会, Japanese - 同種移植後の局所再発に対し同一ドナーからの再移植と大量リンパ球輸注が奏功した急性リンパ性白血病の一例
皆内康一郎, 遠藤知之, 山倉昌之, 小原雅人, 熊野弘毅, 坂井俊哉, 佐藤典宏, 高見昭良, 中尾真二, 臨床血液, 45, 8, 901, 30 Aug. 2004
Japanese - 同種移植後再発に対し同一ドナーからの骨髄非破壊的再移植と大量DLIが有効であったMDSの1例
藤本勝也, 皆内康一郎, 小原雅人, 熊野弘毅, 坂井俊哉, 遠藤知之, 小泉和輝, 小池隆夫, 佐藤典宏, 日本輸血学会雑誌, 50, 1, 145, 145, 31 Mar. 2004
(一社)日本輸血・細胞治療学会, Japanese - CD11c+ dendritic cell subset associates with co-developing dying erythroid progenitor cells from human CD34+ cells in the presence of tumor necrosis factor-alpha.
H Fukaya, WG Xiao, K Inaba, Y Suzuki, M Hirokawa, Y Kawabata, A Komatsuda, T Endo, G Takada, K Sawada, BLOOD, 102, 11, 141B, 141B, Nov. 2003
English, Summary international conference - B細胞性悪性リンパ腫に対するCHOP+Rituximabによるin vivo purgingの効果
遠藤知之, 小原雅人, 熊野弘毅, 坂井俊哉, 藤本勝也, 茂木祐子, 佐藤典宏, 池田久実, 小池隆夫, 臨床血液, 44, 8, 802, 802, 30 Aug. 2003
(一社)日本血液学会-東京事務局, Japanese - 再発・治療抵抗性indolent lymphomaに対するfludarabine併用化学療法の有効性・安全性の検討
藤本勝也, 小原雅人, 熊野弘毅, 坂井俊哉, 遠藤知之, 小泉和輝, 佐藤典宏, 小池隆夫, 臨床血液, 44, 8, 765, 765, 30 Aug. 2003
(一社)日本血液学会-東京事務局, Japanese - 呼吸筋麻ひを呈し,形質細胞腫摘出術が有効であったPOEMS症候群の一例
熊野弘毅, 小原雅人, 坂井俊哉, 藤本勝也, 遠藤知之, 小泉和輝, 矢口裕章, 佐藤典宏, 小池隆夫, 臨床血液, 44, 8, 817, 30 Aug. 2003
Japanese - TNF-alpha inhibits generation of GPA+ cells by CD34+ cells.
WG Xiao, K Koizumi, M Nishio, T Endo, T Koike, K Sawada, BLOOD, 100, 11, 169B, 170B, Nov. 2002
English, Summary international conference - 非ホジキンリンパ腫に対する自家末梢血幹細胞移植併用超大量化学療法後の二次性MDSと染色体異常
藤本 勝也, 坂井 俊哉, 山本 聡, 遠藤 知之, 西尾 充史, 小泉 和輝, 小池 隆夫, 澤田 賢一, 河野 通史, 大西 勝憲, 佐藤 典宏, 池田 久實, 臨床血液, 43, 8, 420, 420, Aug. 2002
(一社)日本血液学会-東京事務局, Japanese - 自家末梢血CD34陽性細胞選択移植後の免疫低下状態に対するin vitro増幅自己活性化Tリンパ球輸注
遠藤 知之, 東 寛, 坂井 俊哉, 藤本 勝也, 山本 聡, 西尾 充史, 小泉 和輝, 佐藤 典宏, 池田 久實, 澤田 賢一, 小池 隆夫, 臨床血液, 43, 8, 450, 450, Aug. 2002
(一社)日本血液学会-東京事務局, Japanese - Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure
M Nishio, S Nakao, T Endo, K Fujimoto, H Takashima, T Sakai, A Bacigalupo, T Koike, K Sawada, BONE MARROW TRANSPLANTATION, 28, 8, 783, 785, Oct. 2001
English - Diminished T-cell recovery after CD34(+) selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus infection
M Nishio, K Koizumi, T Endo, K Fujimoto, T Koike, K Sawada, HAEMATOLOGICA, 86, 6, 667, 668, Jun. 2001
English, Report scientific journal - Stem cell factor protects c-kit positive human erythroid cells from apoptosis.
T Endo, A Oda, Y Haseyama, M Nishio, K Koizumi, Sato, I, Y Amasaki, Y Sato, K Ikebuchi, H Ikeda, T Koike, KI Sawada, BLOOD, 96, 11, 80A, 80A, Nov. 2000
English, Summary international conference - Successful hematologic reconstitution using CD34^+ cells positively selected from cryopreserved autologous peripheral blood stem cells in a patient with malignant lymphoma
ENDO Tomoyuki, SAWADA Ken-ichi, FUJIMOTO Katsuya, YAMAMOTO Satoshi, TAKASHIMA Hidenori, HASEYAMA Yoshihito, NISHIO Mitsufumi, KOIZUMI Kazuki, KOIKE Takao, Rinsho Ketsueki, 41, 8, 681, 686, 30 Aug. 2000
Clinical use of CD34+ cells positively selected from cryopreserved peripheral blood stem cells (PBSC) has been limited, and there have been only a few reports of this procedure, mainly because clump formation decreases the proportion of CD34+ cells that can be recovered. A 49-year-old Japanese woman with non-Hodgkin's lymphoma (NHL) (follicular mixed, B cell, stage IVA) was treated with seven cycles of conventional chemotherapy and achieved partial remission. During hematopoietic recovery after the seventh course of chemotherapy, PBSC were harvested by continuous leukapheresis and cryopreserved. However, clonal rearrangement of the immunoglobulin heavy chain gene was detected in the PBSC by Southern blot analysis. After high-dose chemotherapy, CD34+ cells were positively immunoselected from the cryopreserved PBSC and infused into the patient at 1.97×106/kg. The overall purity and recovery rate of the CD34+ cells were 72.2% and 65.0%, respectively. There were no severe adverse effects after PBSC transplantation, and the time required for recovery of neutrophils to over 0.5×109/l and platelets to over 50×109/l was 11 and 21 days, respectively. Transplantation of CD34+ cells positively selected from cryopreserved PBSC provides engraftment ability similar to that of unmanipulated PBSC., The Japanese Society of Hematology, Japanese - Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies
ENDO Tomoyuki, SAWADA Ken-ichi, FUJIMOTO Katsuya, YAMAMOTO Satoshi, TAKASHIMA Hidenori, HASEYAMA Yoshihito, NISHIO Mitsufumi, KOIZUMI Kazuki, KOIKE Takao, Rinsho Ketsueki, 41, 4, 322, 328, 30 Apr. 2000
日本臨床血液学会, Japanese - Effective CD34(+)-selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia
H Hashimoto, K Sawada, K Koizumi, M Nishio, T Endo, T Takashima, H Kobayashi, T Koike, BONE MARROW TRANSPLANTATION, 24, 12, 1369, 1371, Dec. 1999
English, Report scientific journal - VIPによる多発性骨髄腫(MM)の末梢血幹細胞採取(PBSCH)の検討
西尾充史, 沢田賢一, 藤本勝也, 山本聡, 遠藤知之, 高橋英典, 橋本英明, 佐藤典宏, 池田久実, 日本輸血学会雑誌, 45, 6, 952, 953, 01 Dec. 1999
Japanese - Large scale purification of human blood CD34+cells from cryopreserved peripheral blood progenitor cells.
K Koizumi, M Nishio, H Hashimoto, T Endo, H Takashima, Y Haseyama, N Sato, T Yasukouchi, T Koike, K Sawada, BLOOD, 94, 10, 352B, 352B, Nov. 1999
English, Summary international conference - Stem cell factor prevents Fas-mediated apoptosis of primary cultured human erythroid precursor cells.
M Nishio, A Oda, K Koizumi, Satoh, I, Y Haseyama, T Endo, H Takashima, H Hashimoto, M Fujihara, K Ikebuchi, H Ikeda, T Koike, K Sawada, BLOOD, 94, 10, 264A, 264A, Nov. 1999
English, Summary international conference - 自家末梢血CD34陽性細胞選択移植を施行した悪性リンパ腫の3症例
小泉 和輝, 澤田 賢一, 遠藤 知之, 高島 英典, 橋本 英明, 西尾 充史, 西尾 仁, 高野 弥奈, 安河内 太郎, 佐藤 典宏, International Journal of Hematology, 69, Suppl.1, 216, 216, Apr. 1999
(一社)日本血液学会, Japanese - Autoimmune Thrombocytopenia Following Syngeneic Peripheral Blood Stem Cell Transplantation
NISHIO Mitsufumi, SAWADA Ken-ichi, KOIZUMI Kazuki, ENDO Tomoyuki, TAKASHIMA Hidenori, HASHIMOTO Hideaki, HASEYAMA Yoshihito, KATAGIRI Eri, FUKADA Yoshikazu, TAKANO Hina, TARUMI Katashi, YASUKOUCHI Taro, KOIKE Takao, Rinsho Ketsueki, 39, 8, 580, 585, 30 Aug. 1998
A 35-year-old man with non-Hodgkin's lymphoma (NHL) (follicular small cleaved, B cell, stage IVB) received double myeloablative chemotherapy with syngeneic peripheral blood stem cell transplantation (PBSCT). Although platelet recovery was delayed until day 29 after the second transplantation, thereafter trilineage hematopoietic reconstitution was achieved. The evaluation after PBSCT did not detect any residual tumor. The patient was in good health until day 138, when his platelet count suddenly began falling; on day 150, it had fallen to 1.5×104/μl, and the patient was re-admitted for treatment. The bone marrow was normocellular with a normal count and megakaryocyte structure. Other examinations, including serological tests and computed tomography of the neck, chest, abdomen, and retroperitoneum, did not indicate a recurrence of NHL or reveal the cause of thrombocytopenia. The patient's platelet-associated IgG (PAIgG) level was at 70.9 ng/107 platelets (normal range: 9∼25 ng/107 platelets); a diagnosis of thrombocytopenia due to an autoimmune mechanism such as idiopathic thrombocytopenic purpura (ITP) was made. Prednisolone therapy increased the platelet count and reduced the PAIgG level. Thrombocytopenia with an ITP-like mechanism rarely occurs more than 100 days after autologous or syngeneic stem cell transplantation, and should be taken into consideration as a late complication of PBSCT., The Japanese Society of Hematology, Japanese - PREOPERATIVE INTRAAORTIC ULTRASONOGRAPHY TO DETERMINE RESECTABILITY IN ADVANCED ESOPHAGEAL CANCER
S AKIYAMA, Y KODERA, H SEKIGUCHI, M FUJIWARA, J SAKAMOTO, K KONDO, K ITO, T ENDO, H TAKAGI, BRITISH JOURNAL OF SURGERY, 82, 12, 1671, 1674, Dec. 1995, [Peer-reviewed]
English, Report scientific journal
Research Themes
- 新規Shock and Kill戦略によるHIVリザーバー減少効果の解析
科学研究費助成事業
01 Apr. 2024 - 31 Mar. 2027
遠藤 知之
日本学術振興会, 基盤研究(C), 北海道大学, 24K11628
